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The tumor microenvironment is established and maintained through the complex 
interactions of tumor cells with host stromal elements. Therefore, therapies that target 
multiple cellular components of the tumor may be most effective. Sorafenib, a multi-kinase 
inhibitor, alters signaling pathways in tumor cells and host stromal cells. Thus, we explored 
the potential immune-modulating effects of Sorafenib in a murine HER-2-(neu) 
overexpressing breast tumor model alone and in combination with a HER-2 targeted 
granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting vaccine. In vitro, 
Sorafenib inhibited the growth of HER-2 overexpressing NT2.5 tumor cells, inducing 
apoptosis. Western blot analysis revealed that Sorafenib interfered with ERK MAPK, p38 
MAPK, and STAT3 signaling, but not HER-2 or Akt signaling. It also decreased D-type 
cyclin expression. In vivo, single agent Sorafenib disrupted the tumor-associated 
vasculature and induced tumor apoptosis, effectively inducing the regression of established 
NT2.5 tumors in immune competent FVB/N mice. Immune depletion studies demonstrated 
that tumor rejection was mediated by both CD4+ and CD8+ T cells. Sorafenib treatment 
enhanced tumor clearance induced by vaccination with a GM-CSF-secreting, HER-2-
expressing cellular vaccine in tumor-bearing FVB/N mice relative to either drug treatment 
or vaccination alone. Although the magnitude of the peripheral antigen-specific T cell 
response was unchanged, Sorafenib appeared to enhance antigen-specific T cell 
accumulation at the tumor site.  Overall, these findings suggest that dendritic cell-based 
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Chapter 1: Introduction 
HER2   
The human epidermal growth factor receptor 2 (HER2, also known as c-erbB-2, or 
HER2/neu) is a member of HER family of transmembrane receptor tyrosine kinases.  The 
HER family is comprised of four homologous epidermal growth factor receptors: 
HER1(EGFR/erb1), HER2 (erb2), HER3 (erb3), and HER4 (erb4). These receptors are 
involved in regulating cell growth, differentiation, and survival through signaling via 
PI3K/Akt and Ras/Raf/MEK/MAPK pathways1, 2. While there are many ligands that have 
been identified that can activate individual HER receptors, no ligand has yet been identified 
for HER2.  Upon ligand binding, HER receptors form homodimers and heterodimers with 
other members of the HER family, of which HER2 is the preferential dimerization partner.  
The heterodimerization between HER2 and the other HER receptors in the family allow its 
participation in signal transduction in the absence of a ligand.  Heterodimers involving 
HER2 seem to show particularly high signaling potency compared to other dimerization 
combinations within the HER2 family3.   
In vitro and animal studies have indicated that HER2 gene amplification and protein 
overexpression plays an essential role in oncogenic transformation, tumorigenesis, and 
metastasis4-6. Normal epithelial cells possess two copies of the HER2 gene and expresses 
low levels of HER2 protein on the cell surface.  With oncogenic transformation, HER2 
gene amplification generates more than two gene copies and increased mRNA 
transcription, which results in 10-100 fold increases in HER2 homodimer formation on the 
cell surface.  Therefore, overexpression of the HER2 protein leads to constitutive activation 
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of downstream signaling pathways, which ultimately results in oncogenic transformation 
of cells to cause cancer7. 
HER2+ breast cancer  
Breast cancer is currently the most common cancer in women and is leading cause of cancer 
death in women in Western countries after lung cancer.   Amplification of the HER2 gene 
in addition to overexpression at the messenger RNA or protein levels occur in about 20% 
of invasive breast cancers and corresponds to more aggressive disease and poor prognosis8.  
HER2 status has been shown to be a predictive marker of therapeutic response to HER2-
targeted therapy9.  Also, the accessibility of HER2 on the cell surface makes it a druggable 
target. 
HER2-targeted treatments 
Standard therapy for breast cancer includes surgery, radiation therapy, chemotherapy and 
endocrine therapy10.  Optimal integration of these therapies has led to improvements in 
clinical outcome for breast cancer patients.  More recently, some targeted therapies have 
improved overall survival for those women affected with metastatic disease.  In this 
category, HER2+ breast cancer patients have seen small overall survival benefit with the 
development and FDA-approval of therapies available that target HER2.  Trastuzumab 
(Herceptin) is a HER2-specific monoclonal antibody that binds to the extracellular domain 
of the HER2 protein.  Lapatinib (Tykerb) is a dual HER2/EGFR1 tyrosine kinase inhibitor.  
Pertuzumab (Perjeta) is a monoclonal antibody that binds to the surface HER2 and works 
by inhibiting receptor dimerization and downstream signaling potential.  Trastuzumab 
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emtansine (T-DMI, Kadcyla) is the HER2-specific monoclonal antibody, Trastuzumab, 
conjugated to cytotoxic molecules11.  
The development of these new therapies has improved clinical outcome for patients with 
HER2-positive breast cancer.  However, relapse still occurs with current therapies, 
reflecting acquired resistance in some patients.  Additionally, patients with metastatic 
cancer still eventually progress in their disease and metastatic breast cancer remains 
incurable.  The limitations of current therapies lie in the common toxicities of treatments 
to both malignant and normal tissues and the occurrence of relapse due to outgrowth of 
resistant cancer cells.  Therefore, the ability to successfully combat the disease will rely 
heavily on the development of unique targeted therapies with distinct mechanisms of action 
that preferably impact malignant tissue.    
Immunotherapy for Cancer Treatment 
Immunotherapy provides an attractive option to overcome these distinct resistance 
mechanisms through the utilization the patient’s own immune system to combat their 
disease.  Additionally, immunotherapy allows a mechanism for targeting the malignant 
cells specifically while leaving normal cells unharmed.  Using immunotherapy as a means 
of treating cancer dates back to 1891, when William B. Coley found that killed bacteria 
injected into bone sarcoma resulted in reduced tumor size.  Similar crude bacterial 
mixtures, called “Coley’s toxins,” were used to treat a variety of different cancers from 
1893 to 1963 with varying clinical benefit 12.  Further data to support immunotherapy came 
from clinical trials carried out in the 1980’s in metastatic melanoma and renal cell 
carcinoma.  In these trials, patients were treated with interleukin-2 (IL-2).  Uniquely, it was 
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known that IL-2 would have no direct cytotoxic effects on the tumor.  Instead it was used 
specifically to stimulate the proliferation of cytotoxic T cells (CTLs) 13.  In these studies 
15% of patients showed response and about half of the responsive patients were cured of 
their disease.  This led to the approval of IL-2 by the FDA in the 1990’s as the first 
immunotherapy to treat cancer.  More recently, immunotherapy has gained momentum 
with the FDA approval of sipuleucel-T (Provenge), a dendritic cell based vaccine, for the 
treatment of prostate cancer; and ipilimumab (Yervoy), a monoclonal antibody against 
cytotoxic T lymphocyte antigen-4 (CTLA-4), and Prembrolizumab (Kaytruda), a 
monoclonal antibody specific for PD-1 (programmed cell death-1). These two monoclonal 
antibodies are approved for the treatment of metastatic melanoma 14,15.  
Currently, there is little doubt of immune system’s role both in cancer development and 
successful disease eradication.  As we have gained a deeper understanding of the complex 
molecular and cellular mechanisms that comprise the immune system, we have 
subsequently enhanced the development of new therapies to induce and manipulate the 
anti-tumor immune response.  One of these immunotherapeutic approaches has been cancer 
vaccines.  
Cancer Vaccines 
Successful therapeutic cancer vaccines will result in both primary activation of the immune 
system to recognize and attack cancer cells within the host, and the development of 
secondary immunological memory that prevents reoccurrence.  In order to accomplish this, 
cancer vaccines consist of an immunogenic tumor antigen to stimulate the activation of 
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helper T cells and CTLs that can recognize tumor cells and initiate tumor cell destruction 
mechanisms16.      
Because it remains unclear what the most potent tumor antigens are, one approach has been 
to use whole cells for vaccination.  Early generation cancer vaccines took the form of killed 
tumor cells or tumor cell lysates mixed with bacteria adjuvants in an attempt to amplify 
anti-tumor immunity17, 18.  Next generation vaccines replaced the crude bacteria-lysate 
mixtures with genetically modified tumor vaccines.  In the 1960’s, Lindermann and Klien 
were able to show that tumor cells infected with influenza virus were able to generate 
enhanced tumor cell immunogenicity19.  Cells have also been transduced with viral genes 
or allogeneic MHC genes in an attempt to enhance systemic immune responses 20, 21.   
Another class of genetically modified cell-based vaccines takes advantage of the ability of 
cytokines and co-stimulatory molecules constitutively expressed on the vaccine cells to 
activate local inflammatory response, sparing systemic toxicity.   Specifically, granulocyte-
macrophage colony stimulating factor (GM-CSF) has been shown to be most potent in its 
ability to modify tumor immunogenicity22.   
The activity of GM-CSF modified vaccines lies in their effectiveness at promoting the 
activation and maturation of dendritic cells (DCs) at the vaccine site.  DCs are central to 
activation of naïve T cells in peripheral lymphoid tissues to mount a successful immune 
response.  A large number of clinical trials in a variety of cancers have proven the efficacy 
of GM-CSF transduced vaccines to boost patient’s anti-tumor immune responses23-26 .  
These trials also pointed to an important role of conventional therapies, such as 
chemotherapy, to have an effect on vaccine-induced immune responses.  This was clearly 
demonstrated in patients with metastatic breast cancer, where GM-CSF-secreting whole 
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cell vaccination in the presence of immune-modulating doses of cyclophosphamide and 
doxorubicin enhanced HER2-specific antibodies and HER2-specific DTH responses27 .   
In order to effectively implement cancer vaccines in the clinic, it is necessary to have a 
basic understanding of the anti-tumor immune response and the subsequent dysregulation 
that can occur in cancer patients.  Successful cancer vaccination therapies must reprogram 
the immune response to actively target cancer cells and simultaneously relieve suppressive 
mechanisms that can hinder productive anti-tumor immune responses.   
The anti-tumor immune response- T cell activation and Antigen Presenting Cells 
The immune response mounted against a tumor relies on both the innate and adaptive arms 
of the immune system.  Cells in the innate immune system are not antigen specific.  Instead, 
innate immune cells actively survey the host and recognize cell-surface stress-associated 
and danger-associated molecular patterns.  For example, natural killer (NK) cells can 
recognize “non-self” or “stressed self” cells in the host28.  Additionally, antigen presenting 
cells (APCs), such as DCs present in the periphery, can recognize danger signals through 
interaction of cell surface receptors.  These danger signals include: Toll receptor or NOD-
like receptors (NLRs) ligation; retinoic acid-inducible gene 1 (RIG1) sensing of RNA; or 
stimulator of interferon genes (STING) pathway activation as a result of cytosolic DNA 
recognition 29, 30.  Upon activation, DCs undergo maturation to upregulate co-stimulatory 
molecules and act as messengers to relay the danger signals to secondary lymphoid tissues 
where they stimulate the activation of the adaptive arm of the immune response.   
The adaptive immune response, unlike innate immunity, is antigen specific.  There are two 
arms to adaptive immune responses, humoral immunity and cell-mediated immunity.  The 
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humoral response is dependent on B cells and ultimately leads to the production of 
antibodies.  Cell-mediated immune responses depend on T cells.  Whereas B cells only 
respond to intact antigen and thus recognize extracellular antigenic epitopes to mount a 
response, T cells are able to respond to both extracellular and intracellular proteins. T cell-
mediated immune responses require multiple steps including: the clonal selection of 
antigen-specific cells, activation and proliferation of the selected cells in secondary 
lymphoid tissues, subsequent trafficking to the tumor site, and lastly, the ability to execute 
their specific effector functions once within the tumor31.  
There are two major functionally different types of T cells defined by the cell surface 
expression of distinct co-receptors proteins: CD4+ helper T cells and CD8+ cytotoxic T 
cells.  As their name implies, cytotoxic CD8+ T cells are able to kill target cells directly 
whereas CD4+ helper T cells activate APCs and provide “help” to enhance CD8+ T cell 
activation.  CD4+ T cells also provide help to B cells to stimulate antibody production.   A 
major differentiating factor between CD4+ and CD8+ T cells is the context by which their 
T cell receptors recognize and bind to antigenic peptides on histocompatibility complex 
(MHC) molecules. There are two types of MHC molecules, MHC class I and MHC class 
II, which differ in their structure and expression levels within the body.  MHC class I 
molecules are expressed on all nucleated cells in the body and present intracellular peptides 
to CD8+ T cells.  The proteasome pathway within the cell processes proteins and cleaves 
them into peptide fragments ranging between 8-12 amino acids in length.  These peptide 
fragments are loaded on the MHC class I molecules for presentation to CD8+ T cells32, 33.  
MHC class II molecules are expressed only on a specialized subset of APCs, including B 
cells, DCs, and macrophages.  APCs take up exogenous proteins (or extracellular microbes) 
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and process these proteins through the lysosomal degradation pathway.  This pathway 
results in protein processing into peptides ranging from 10-25 amino acids in length 32, 34.  
These peptides are loaded onto MHC class II molecules and presented on the surface of 
APCs to activate CD4+ T helper cells.   
During development, T cells undergo a selection process in the thymus.  Positive selection, 
also known as MHC restriction, ensures only those T cells expressing T cell receptors 
(TCRs) that recognize and bind self-MHC molecules are allowed to survive.  Thymic 
stromal cells are responsible for mediating positive selection.  CD4+ or CD8+ cell fate is 
determined by the specificity of the TCR to recognize and bind invariant sites on either 
MHC class I or MHC class II 35, as binding of both the TCR and a single co-receptor is 
necessary to promote T cell survival.   The cellular signals that promote one cell lineage 
over the other seems to depend, at least in part, through differential leukocyte-specific 
tyrosine kinase (Lck) signals upon engagement of the TCR receptor with either co-receptor.  
Additionally, T cells also undergo negative selection which eliminates T cells with very 
high avidity for self-MHC/peptide complexes.  The process of negative selection is 
mediated primarily by APCs in the thymus, such as DCs and macrophages.  T cells that 
react too strongly with self-antigen are induced to die by apoptosis.  Under normal 
circumstances, this prevents the maturation of T cells that would attack the host’s own 
cells, thereby avoiding autoimmunity35. 
T cells that have survived selection in the thymus are then carried in the blood to peripheral 
lymphoid tissues to interact with their specific antigens and undergo proliferation.  T cells 
require two signals for activation.  Signal 1 is the result of the interaction of an antigenic 
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peptide with the TCR-CD3 complex36.  The CD3 complex is associated with the TCR and 
is required for proper TCR expression and signal transduction upon activation.  The CD3 
complex is composed of the molecules CD3CD3andCD3δ in addition to a  chain, 
which is a disulfide-linked homodimer37.  Antigen recognition in the context of 
peptide:MHC initiates tyrosine phosphorylation of immune-receptor tyrosine–based 
activation motifs (ITAMs) on the intracellular regions of the CD3 complex and the  chain 
by the Src kinase LcK38.  These phosphorylated ITAMs provide a docking point for the 
recruitment of Syk family kinase, Zeta-activated protein 70kDa (Zap70).  Zap70 then 
phosphorylates the protein linker for the activation of T cells (LAT), recruiting Slp76, 
which complexes with LAT proteins after phosphorylation by Zap70 39.  This LAT-Slp76 
interaction provides a docking site for several signaling effectors through binding to the 
phosphotyrosine binding sites.  One of these effectors, phospholipase Ctransduces 
signals resulting in activation of Ras and mitogen-activating protein kinase (MAPK) as 
well as the influx of calcium into the cytosol.  This signaling results in the activation of 
transcription factors Fos and Jun that form the AP-1 complex, the translocation of nuclear 
factor of activated T cells (NFAT), and nuclear factor-NF-These three factors act 
together to activate the transcription of interleukin-2 (IL-2) gene40. 
Engagement of the TCR-CD3 complex alone is insufficient for T cell activation.  A second 
signal is required to achieve optimal T cell activation and proliferation.  The principal 
“second signal” is provided by interactions between the CD28 molecule on T cells and B7 
proteins on APCs41.   Ligands for B7 are CD28 and CTLA-4 (CD 152), which act 
antagonistically with each other.  Signaling through CD28 and B7 leads to the 
phosphorylation of Src-family resulting in the recruitment of several downstream proteins, 
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including Grb2, Vav, and ITK that ultimately augment IL-2 production and activate T cell 
proliferation.  Conversely, engagement of CTLA-4 attenuates T cell proliferation signals40.  
T cell tolerance 
T cell tolerance, which is the ability of the immune cells to differentiate self from non-self, 
is the foundation of a healthy functioning immune response. As mentioned previously, this 
prevents reacting to self-antigens and resulting autoimmunity.  However, these self-
protective mechanisms also provide the biggest challenge for successful cancer vaccines.  
As tumors arise from altered “self” cells; an inadequate immune response to “self” permits 
tumor growth.  Therefore, successful vaccination requires breaking immune tolerance to 
recognize and attack host tumor cells.       
T cell tolerance is maintained at two levels, central and peripheral tolerance.  Central 
tolerance occurs by deletion of self- reactive T cells in the thymus.  As described earlier, 
thymocytes expressing TCRs that have high-avidity for self-peptide-MHC are induced to 
undergo apoptosis, thus preventing potentially self-reactive T cells from entering the 
circulation 42.   As all potential self-antigens are not expressed in the thymus, peripheral 
tolerance mechanisms come into play to inhibit circulating self-reactive T cells.  Three 
major mechanisms of peripheral tolerance include: deletion, ignorance, and anergy. 
Deletion of self-reactive T cells in the periphery occurs by a mechanism similar to that in 
the thymus- induction of apoptosis.  Both Bim signaling and Fas-mediated death receptor 
signaling cooperate in tandem to ensure killing of T cells that respond too strongly to self-
antigens in the circulation.  Fas (CD95) is a death-domain-containing receptor that is 
activated by binding to its corresponding ligand FasL (CD95L).  The activation of the Fas 
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receptor on T cells by cells containing FasL, induce both the up-regulation of FasL on T 
cells themselves as well as that activation of an intracellular death-inducing signaling 
complex (DISC).  DISC activates caspases to promote apoptosis by activation-induced cell 
death 43,44.  Concurrently, Bim activates Bax/Bak, which causes mitochondrial 
permeabilization to induce apoptosis45.    
Ignorance occurs as a result of low level antigen expression or antigen sequestration, which 
results in T cells that remain naïve due to lack of antigen exposure46.  T cell activation in 
the absence of a second signal results in hyporesponsiveness, termed “anergy.” Anergy 
results in repression of TCR signaling and decreased IL-2 expression42.  Additionally, 
inhibitory signaling molecules can be engaged as a second signal on T cells. One such 
example is programmed cell death 1 (PD-1) and its ligands PD-L1 and PD-L2.  PD-1 
association with its ligand results in PD-1 ligation with the TCR.  This ligation activates 
phosphatases that attenuate T cell proliferation pathways 47.  In this way, PD-1 interactions 
can limit the expansion of self-reactive T cells.  PD-1 signaling can be manipulated by the 
tumor to prevent expansion of tumor-reactive T cells as well 48.      
Regulatory T cells 
CD4+ T regulatory cells (Tregs) are produced in the thymus, forming a functionally distinct 
T-cell subpopulation in the periphery.  A distinguishing feature of Tregs is their expression 
of the transcription factor, forkhead box p3 (FoxP3)49. FoxP3 controls the expression of 
several characteristic genes for cell surface molecules, such as the alpha chain of the IL-2 
receptor, CD25, glucocorticoid-induced tumor necrosis factor (TNF) receptor (GITR) 
family regulated gene and CTLA-4, which are also highly expressed in conventional T 
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cells after TCR stimulation50,51. FoxP3 inhibits TCR-activation-dependent production of 
effector cytokines including IL-2 and IFN-γ. As possible mechanisms of suppression, it 
has been shown that FoxP3+ Tregs exert suppression by cell-to-cell contact with APCs, 
such as DCs. FoxP3+ Tregs are also able to secrete immunosuppressive cytokines such as 
interleukin 10 (IL-10), transforming growth factor β (TGF-β) and interleukin 35 (IL-35)52.  
In this way, Tregs are capable of suppressing a wide variety of immune responses against 
self-antigens, including tumor antigens.  
Immune System Evasion- Immunoregulatory Components of the Tumor 
Microenvironment 
The host antitumor immune response can sculpt tumor growth, invasion, and metastasis in 
a variety of ways. The prevention of immune cell access into the tumor, the accumulation 
of inhibitory Tregs and/or other suppressive cells, the activation of negative 
immunoregulatory pathways, and the dysregulation of effector T cells are all mechanisms 
by which tumors evade the host immune system.  
Notably, the presence of large numbers of tumor infiltrating T lymphocytes (TILs) has 
been reported to be an indicator of good prognosis in multiple solid tumors53-56.   Therefore, 
it is not surprising that physically preventing effector CD8+ T cell infiltration or inhibiting 
their activity once they gain access to the tumor might be a means by which tumors protect 
themselves from immune attack, enabling them to persist within the host.  Additionally, 
distinct components of the tumor microenvironment can suppress active antitumor T cell 
responses in multiple ways. Tumor endothelial cells (TECs) present at the blood-tumor 
barrier act as gatekeepers, regulating the homing, adhesion and trans-endothelial migration 
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of lymphocytes into the tumor57.  TECs can create a protective barrier to block or disrupt 
trans-endothelial T cell migration and survival within the tumor microenvironment.  Many 
TECs express FasL and induce the death of Fas-expressing T cells attempting to gain 
access to the tumor57.   
Additionally, both innate and adaptive immune cells that gain access to the tumor site can 
contribute to disease progression by corruption of the inherent protective inflammatory 
response mounted against the tumor to promote immune evasion. For example, alterations 
in tumor cell biology can lead to decreased susceptibility to killing, and alterations in APCs 
can lead to faulty T cell priming and promote T cell dysfunction. Both the induction of 
suppressive cytokines and the expression of negative immunomodulatory molecules within 
the tumor microenvironment can dampen immune responses. High levels of IL-10 and/or 
transforming growth factor (TGF-β), the expression of FAS or FASL, PDL-1 PDL-2, 
and the expression of immunomodulatory enzymes like indoleamine 2,3-dioxygenase, 
(IDO), arginase (ARG) or inducible nitric-oxide synthase (iNOS) can inhibit tumor 
immunity58. The major producers of these immunoregulatory molecules include 
tolerogenic DCs, Tregs, myeloid-derived suppressor cells (MDSCs), and tumor-associated 
macrophages (TAMs).  
Of these suppressive cell types, breast cancer is characterized by having a large population 
of TAMs, and experimental models have shown multiple pathways by which TAMs can 
influence the surrounding tumor microenvironment59. TAMs have been shown to secrete 
pro-angiogenic factors, such as VEGF, that support the development of neo-vasculature 
paramount to tumor survival and metastases to distant sites.  Additionally, TAMs can 
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secrete cytokines and other factors that can suppress the induction of local pro-
inflammatory antitumor response60 . 
Vaccine strategies to reprogram the immune response to cancer  
Despite the many immunosuppressive mechanisms that blunt productive anti-tumor 
responses, it is clear that the presence of immune cell infiltrates are associated with 
improved survival and response to therapy in some patients. These observations imply that 
the tumor microenvironment represents a therapeutic target that can be manipulated to 
promote tumor regression in more patients. Therefore, preclinical work has aimed to 
integrate tumor vaccines with established cancer drugs in an effort to target cancer cells 
directly through cytotoxic effects, as well as potentially augmenting vaccine-induced 
immune responses through modulating immune cells within the tumor microenvironment.   
A Preclinical Model of Antigen-Specific Immune Tolerance 
The neu-N transgenic mouse was derived from parental FVB/N mice by placing the rat neu 
proto-oncogene under the control of the mammary specific promoter, mouse mammary 
tumor virus (MMTV), resulting in mammary tissue specific expression of the rat HER-2 
protein.  As a result of overexpressing HER-2, neu-N mice spontaneously develop 
mammary tumors at about 4-6 months 61.  These tumors were used to develop cell lines 
that express high levels of rat HER-2, called NT2.5.  These cell lines are used for orthotopic 
tumor implants to examine HER2 responses in parental FVB/N where rat HER-2 is 
immunogenic, and in neu-N mice where it is not due to immune tolerance. 
A whole cell vaccine was created from 3T3 fibroblast cells genetically modified to 
constitutively secrete GM-CSF and deliver high amounts of tumor antigen through the 
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overexpression of rat HER-262.  Tumors were orthotopically implanted into the mammary 
fat pads of FVB/N mice and allowed to reach ~0.5 centimeter in size (about 1 week 
following implant).  Vaccination of these mice with the HER-2 overexpressing GM-CSF-
secreting 3T3 vaccine cells inhibited tumor cell growth and ultimately resulted in 100% 
tumor resolution in these mice.  Evaluation of specific anti-tumor responses in these mice 
showed that FVB/N mice develop high levels of antibodies that are specific for HER-2 in 
addition to a population of high avidity T cells that are specific for the immunodominant 





To this end, previous successful animal and human studies have examined combining 
vaccination with chemotherapy and Trastuzumab27,62,65-68.  These combinations were 
shown to enhance vaccine induced immune responses, through measuring both HER-2 
specific antibody production and HER-2 specific T cell responses.  Studies in these models 
have led to clinical trials that have examined the use of a human vaccine in the clinic for 
patients with HER-2 positive as well as HER-2 negative disease and have seen some 
success27. 
These preclinical studies were also expanded to explore the potential use of angiogenesis 
inhibitors in combination with vaccine.  Despite many efforts to incorporate anti-
angiogenic therapy into a treatment standard for breast cancer, they have not been 
successful.  Therefore, antiangiogenic therapy may work best in combination therapy rather 
than as single agents69.  Previous published work focused on the immune based activity of 
DC101, a monoclonal antibody that targets vascular endothelial growth factor receptor 2 
(VEGFR-2).  VEGFR-2 is found on endothelial cells and has been shown to play a critical 
role in initiating the formation of new vessels that is hallmark of cancer development.  
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Treating tumor-bearing FVB/N mice with DC101 resulted in tumor regression when 
compared with IgG controls.  Tumor resolution was accompanied by increased HER-2 
specific T cells even in the absence of vaccination.  T cell depletion studies in mice treated 
with DC101 demonstrated a dependence on both CD4+ and CD8+ T cells for drug 
efficacy70.  Giving DC101 sequenced with HER-2 targeted GM-CSF vaccination resulted 
in both further enhancement of tumor resolution compared to either single therapy agent, 
and enhanced T cell responses against the tumor, specifically, against the immunodominant 
epitope of HER2.  
Given the problem of development of acquired resistance with many VEGF- targeted 
therapies, multi-tyrosine kinase inhibitors (TKIs) are an attractive option to target 
angiogenesis given their ability to concurrently target other compensatory pathways 
important in the growth and development of cancer cells.  One such TKI, Sorafenib 
(Nexavar) is a multiple serine/threonine kinase inhibitor that was originally designed to 
inhibit Ras kinase activity but was later shown to have significant activity against several 
other receptor tyrosine kinases involved in neovascularization and tumor progression, 
VEGFR-2, VEGFR-3, platelet-derived growth factor (PDGFR)- Flt-3, and c-KIT 71.  
Sorafenib has been approved for the treatment of renal cell carcinoma (RCC), 
hepatocellular carcinoma (HCC) and more recently for the treatment of differentiated 
thyroid cancer (RTC)72-74.     
Objectives: 
The hypothesis of this thesis was Sorafenib modulates immune cells within the tumor 
microenvironment to enhance tumor rejection and support the anti-tumor immune response 
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to improve the efficacy of DC-based, HER-2 targeted, GM-CSF-secreting vaccination.  
This was investigated first by examining the effect of single agent Sorafenib on immune 
cells within the breast tumor microenvironment.  The HER2-overexpressing cell line, 
NT2.5, was be used to analyze the effect of Sorafenib on HER-2 over-expressing breast 
cancer cells both in vitro and in vivo.  Given the reported potential immune modulating 
effects of TKIs on cells within the tumor microenvironment, the interaction of Sorafenib 
with immune cells was determined.   Specifically, the effect of Sorafenib on T cells and 
macrophages was analyzed.   Finally, the therapeutic and immune effects of partnering 
Sorafenib with DC-based vaccination were investigated.    These studies support the 
hypothesis that Sorafenib can be successfully re-purposed as a partner for immunotherapy, 
not only by inducing increased cell death and inhibiting angiogenesis, but by acting through 
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Chapter 2: Characterizing the Mechanism of Therapeutic Activity of Sorafenib in 
HER2+ Breast Cancer in FVB/N mice  
Introduction: 
The tumor microenvironment is established and maintained through the complex 
interactions of tumors cells with host stromal elements. Therefore, multi-targeted drugs 
and combination therapies that target multiple cellular components of the 
microenvironment may be the most effective strategy to improve survival in patients with 
breast cancer.  One principle targetable component of the tumor microenvironment is the 
vascular niche, where angiogenesis occurs.   
Angiogenesis is defined as the development of a neo-vasculature from pre-existing blood 
vessels.  Angiogenesis is now recognized as a hallmark of cancer development since the 
ability of cancer cells to acquire new blood vessels is paramount to support tumor cell 
proliferation and growth by providing necessary oxygen and nutrients to the tumor site1.  
Angiogenesis is also necessary for the metastasis of cancer cells to distant sites.  Beginning 
in the 1970’s when Judah Folkman first recognized that tumor growth is dependent on 
angiogenesis, significant investments have been made in the development of anti-
angiogenic therapy for the treatment of cancer in the clinic2. As a result of this research, 
inhibitors of angiogenesis have been developed.   
In cancer development, VEGF signaling is a major player in the “angiogenic switch” which 
is the rapid increase in blood vessel formation to support tumor growth and development 
when tumors reach a size beyond 2mm2 3.   Therefore, one strategy to target angiogenesis 
is through the use of therapies that target various aspects of VEGF signaling.  Most notable 
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is the first clinically approved inhibitor of angiogenesis, Bevacizumab (Avastin).     
Bevacizumab, a humanized monoclonal antibody, works mainly by binding to the 
biologically active forms of VEGF thereby preventing its interactions with VEGF 
receptors4.  Despite a modest increase in progression free survival with the use of single 
agent Bevacizumab, many patients do ultimately progress due to therapeutic resistance5,6.   
Given the problem of acquired resistance to anti-VEGF therapy, TKIs are an attractive 
option to target angiogenesis in their ability to also target other compensatory pathways 
important in the growth and development of cancer cells7,8.  Notably, targeting the immune 
system has been shown to play a role in the antitumor effect of many conventional cancer 
therapies, including angiogenesis inhibitors, such as TKIs9 .   
Previously, the impact of standard and novel cancer drugs on the immune system was 
explored10. It was reported that the VEGFR-2-specific monoclonal antibody DC101 not 
only disrupts the tumor-associated vasculature, but also promotes T cell-dependent, 
immune-mediated tumor rejection11.   These observations suggest that therapies targeting 
multiple cellular components of the tumor may be more effective than therapies that only 
target a single cellular element within the tumor. Several groups have investigated the 
immune-modulating effect of the TKI, Sunitinib, but less is known about the effects of 
Sorafenib on the immune system12,13.   Accordingly, these studies have been expanded to 
explore the immune-based activity of Sorafenib, a promiscuous small molecule kinase 
inhibitor that blocks signaling in both tumor cells and host endothelial cells14.  
Sorafenib is a small molecular inhibitor of angiogenesis designed to inhibit 
RAF/MEK/ERK signaling, with a number of off- target effects including the inhibition of 
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wildtype and mutant BRAF, STAT3, and the receptor tyrosine kinases VEGFR2, 
VEGFR3, and PDGFR-. It is FDA- approved for the treatment of HCC, RCC, and DTC 
15-17, and is under investigation in other tumor types as well. Sorafenib has been reported 
to support tumor immunity by decreasing the frequency of CD4+CD25+FoxP3+ Tregs 
without impacting the function of peripheral effector T cells in patients with RCC18. 
Conversely, Sorafenib has been shown to inhibit DC function, reducing DC maturation, 
migration, and T cell priming19. Most data support an inhibitory effect of Sorafenib on 
tumor-specific immunity 19-21 but the variable immune effects of Sorafenib suggest they 
could be context-dependent. 
Given the established clinical indications for Sorafenib, the increasing use of 
immunotherapy in the clinic, and the complex immune effects of Sorafenib, the immune-
modulating effects of Sorafenib were investigated.  First, the effect of Sorafenib on the 
growth characteristics and signaling pathways of HER-2-expressing NT2.5 mammary 
tumor cells in vitro was determined. In vivo tumor regression with Sorafenib treatment was 
examined.  Finally, the effect of Sorafenib on the immune system was analyzed through 
depletion studies.  The results of these studies identified a unique immune-based 




Materials and Methods: 
Mice 
FVB/N mice were purchased from Harlan (Frederick, MD) and 8 to 12 week old mice were 
used in experiments.  Animals were housed in pathogen-free conditions and were treated 
in accordance with institutional and AAALAC policies. All protocols were approved by 
the Animal Care and Use Committee of Johns Hopkins University. 
Reagents 
Sorafenib was purchased from LC Laboratories (Woburn, MA). For in vitro studies, 
sorafenib was dissolved in dimethyl sulfoxide (DMSO) and further diluted in culture 
medium to the required concentration with the final concentration of DMSO concentration 
less than 0.2%. The p38 pathway inhibitor SB203580 was purchased from Sigma-Aldrich 
(St. Louis, MO). The ERK pathway inhibitor U0126 was purchased from Invitrogen 
(Carlsbad, CA). Antibodies for p-STAT3 (Tyr705), STAT3, p-ERK1/2 (Thr202/Tyr204), 
ERK1/2, p-p38 (Thr180/Tyr182), p38, p-AKT (Ser473), AKT, p-HER2 (Tyr877), HER2, 
Cyclin D1, Cyclin D2, Cyclin D3, BCLXL, BCL2, and activated caspase 3 were all 
purchased from Cell Signaling Technologies (Beverly, MA). The actin antibody was 
purchased from Calbiochem (San Diego, CA). Rabbit anti-mouse PECAM/CD31 antibody 
was purchased from Abcam (Cambridge, MA).  Clodronate liposomes were provided by 
Dr. Nico van Rooijen (Vrije Universiteit, VUMC, The Netherlands).  The α-asialo GM1 






Cell Lines and Media 
The NT2.5 tumor cell line, derived from a spontaneous tumor of a neu-N transgenic 
mouse, was grown as previously described22. 
Cell Proliferation Assays 
NT2.5 cells were placed in 96-well plates at 104 cells per well in complete growth media 
overnight. During drug treatments, media was replaced with media containing 0.5% FBS 
and 0μM-10μM Sorafenib in a final volume of 200μl. Final concentrations of DMSO were 
normalized within each experiment. At each time point, 100μl of media was removed and 
20μl of CellTiter 96 Aqueous One Solution (Promega) was added for 2 hours at 37oC. 
Measurements were made at 2, 24, 48, and 72 hours at 490nm. Cell free wells containing 
media and CellTiter solution were used as blank controls.   
Western Blotting 
2×106 NT2.5 cells were placed in 6-well plates overnight in complete growth media.  To 
analyze the effects of Sorafenib on HER-2, ERK, MAPK, p38 MAPK, STAT3 and AKT 
signaling, media was changed to media containing 0.5% FBS and incubated for 2 hours 
with 0M-10of Sorafenib.  To analyze cyclin expression, cells were incubated for 6-7 
hours with 5andM Sorafenib, U0126 (MEK/ERK inhibitor) or SB203580 (p38 
inhibitor).  After the incubation period, cells were lysed in ice-cold CellLytic cell lysis 
reagent (Sigma) supplemented with Phosphatase Inhibitor Cocktail 2 (Sigma) and EDTA-
free protease inhibitor cocktail from Roche Diagnostics (Basel, Switzerland) for 5-10 
minutes on ice. Cell lysates were scraped from 6-well plates, collected and centrifuged for 
10 minutes at 10,000 RPM. Lysates were mixed 1:1 with Laemmli sample buffer and 
boiled for 8 minutes. Samples were subjected to SDS-PAGE on 4-15% gradient gels 
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(BioRad, Hercules, CA) and transferred to Amersham Hybond-ECL (GE Healthcare, 
Piscataway, NJ). Membranes were blocked for 1 hour in 5% Milk in TBS-Tween (w/v), 
and then incubated overnight with primary antibodies in 5% BSA in TBS-Tween (w/v) at 
the dilution recommended on the product data sheet. After washing, membranes were 
incubated with HRP-conjugated Goat--Rabbit IgG (Cell Signaling Technologies) for 30 
minutes at room temperature, washed, and developed using HyGLO Quickspray (Denville 
Scientific, Metuchen, NJ). Membranes were stripped with Restore Western Blot Stripping 
Buffer (Thermo Scientific, Rockford, IL) according to the manufacturer’s instructions, 
then blocked and reprobed. 
Immunohistochemical staining 
Tumors were fixed in formalin for 24 hours, paraffin- embedded and sectioned at 5uM by 
the JHMI Pathology Core.  Sections were stained with H&E or retained for 
immunohistochemistry at the JHMI Oncology Tissue Service Center.  Vascularization and 
apoptosis were analyzed with antibodies specific for PECAM/CD31 (Cell Signaling) and 
cleaved caspase-3 (Abcam) respectively.  Antigen retrieval was carried out for 45 minutes 
in HTTR steam (Target Retrieval Solution; Dako) followed by incubation with primary 
antibody for  45 minutes at room temperature.  Slides were incubated with Power Vision 
Poly-HRP anti-rabbit IgG secondary antibody for 30 minutes at room temperature. Slides 
were developed with 3, 3’ diaminobenzidine (Sigma Fast DAB tablets) and slides were 
counterstained with Mayers hematoxylin (Dako).  Images were captured under light 
microscopy at 10x magnification (E600, Nikon).  Three independent high-powered 
viewing fields were captured and staining was quantified using AR-Elements Microscope 




FVB/N mice were challenged subcutaneously with 5×106 NT2.5 tumor cells in the right 
mammary fat pad, followed by vaccination 10-14 days later.  Sorafenib (30mg/kg) was 
administered in 100μl daily Monday through Friday by oral gavage with a feeding needle 
beginning the day of vaccination. A viscous vehicle composed of 30% (w/v) Cremophor 
EL, 30% (w/v) PEG 400, and 10% ethanol, 10% glucose (Sigma-Aldrich) was used both 
to dissolve Sorafenib and administered as the vehicle treatment control. Mice were 
monitored for tumor growth and onset twice weekly. Tumor growth was determined by 
measuring tumor diameter in two perpendicular dimensions with calipers. Mean tumor size 
for an experimental group included only those mice with measureable tumors. 
Depletion Experiments 
CD4+ and CD8+ T cells were continuously depleted using GK1.5 and 2.43 antibodies as 
previously described22.  Natural killer cells were depleted by twice weekly intraperitoneal 
(i.p.) injections of α-asialo GM1antibody. Macrophages were depleted by i.p. injection of 
clodronate liposomes weekly.  Depletions were initiated one week prior to tumor challenge 
and maintained throughout the experiment. 
Statistical Analysis 
Statistical analysis was conducted either in Microsoft Excel or GraphPad Software using 
an unpaired, two-tailed Student’s t-test, assuming equal population variances to determine 




Sorafenib inhibits the growth of HER-2 over-expressing breast tumor cells in vitro 
First, the effect of Sorafenib on the HER-2 over-expressing breast tumor cell line NT2.5 in 
vitro was examined.  Sorafenib treatment inhibited NT2.5 cell growth, with a decrease in 
cell viability observed at concentrations between 1 to 10μM (Figure 1A). Flow cytometric 
analysis of Sorafenib treated NT2.5 cells stained with Annexin V and 7-AAD revealed a 
concentration-dependent increase in apoptosis (Figure 1B). The effect of Sorafenib on 
downstream targets of the HER-2 pathway was also investigated.  Sorafenib interfered with 
ERK/MAPK, p38 MAPK, and STAT3 signaling, shown by decreased expression of the 
phosphorylated proteins at higher treatment concentrations.  HER-2 or AKT signaling were 
not affected by Sorafenib treatment (Figure 1C).  Sorafenib also decreased the expression 
of the G1/S cyclins D1, D2, and D3 in NT2.5 cells, whereas Bcl2 and BclXL expression 
were not affected (Figure 1D).  
MAPK signaling is required for the expression of cyclin D1, whereas cyclin D3 can be 
controlled by additional pathways23.  Therefore, the effect of Sorafenib on these D-type 
cyclins relative to specific inhibitors of the ERK/MAPK and the p38 MAPK pathways was 
analyzed.  Sorafenib inhibited cyclin D1 to a greater extent than either of the two specific 
MAPK pathway inhibitors, suggesting that the mechanism of NT2.5 growth inhibition by 
Sorafenib is dependent on both arms of the MAPK signaling pathway.  However, unlike 
the either single arm MAPK inhibitors, Sorafenib also inhibited cyclin D3 (Figure 1D).  
Collectively, these data demonstrate that Sorafenib treatment induced apoptosis and 
inhibited cell growth of NT2.5 cells in vitro through MAPK-dependent and -independent 
mechanisms.    
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Sorafenib causes regression of HER-2 over-expressing breast tumors in vivo  
The ability of Sorafenib to inhibit the growth of established NT2.5 tumors in vivo was then 
examined in immune competent FVB/N mice.  Sorafenib monotherapy enhanced NT2.5 
tumor regression in tumor-bearing FVB/N mice compared with vehicle-treated control 
mice (Figure 2A and B).  Immunohistochemistry analyses of tumors harvested 12 days 
post-treatment showed that Sorafenib treatment increased the disruption of tumor-
associated vasculature.  Decreased endothelial cell-specific PECAM/CD31 staining was 
observed in tumors from Sorafenib treated mice compared to tumors from vehicle treated 
mice (Figure 2C).  Sorafenib treatment also resulted in an increase in tumor cell death.  
Tumors from Sorafenib treated mice showed an increase in staining for cleaved caspase-3 
compared to the tumors of mice receiving vehicle treatment (Figure 2D). Taken together, 
these data suggest that Sorafenib inhibits NT2.5 breast tumor cell growth by inhibiting 
angiogenesis and inducing apoptosis in vivo.  
Sorafenib-mediated tumor clearance is T cell dependent 
Studies selectively depleting distinct immune cells were conducted to evaluate the potential 
immune-dependent effects of Sorafenib.  Selectively depleting either CD4+ or CD8+ T 
cells partially inhibited the efficacy of Sorafenib, whereas depleting both T cell subsets 
completely abrogated the anti-tumor effect of Sorafenib (Figure 3A and 3B). Depletion of 
NK cells or macrophages had no effect on the ability of Sorafenib to inhibit tumor growth 
(Figure 3C and 3D).   In animals cured of their tumors by Sorafenib treatment, drug was 
withdrawn for one week and mice were re-challenged with 5×106 NT2.5 cells on the 
contralateral side. No new tumor development was observed at the secondary tumor 
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challenge site.  2 out of 6 mice developed recurrence at the original tumor site, most likely 
through aquired drug resistance or the activation of immune evasion pathways (Figure 3B 
and C).  These data indicate that Sorafenib treatment induces tumor rejection that is in part 
dependent on T cells. Moreover, protection from a second tumor challenge suggests that 






Figure 1: Sorafenib Inhibits growth of HER2-overexpressing cells in vitro 
A,NT2.5 cells were treated in vitro with varying concentration of Sorafenib from 0-10uM 
and analyzed for growth by MTT assay 24, 48 or 72 hours post-treatment. B, NT2.5 cells 
were treated with Sorafenib for 24hrs and stained for Annexin V and 7-AAD and analyzed 
by flow cytometry.  C, NT2.5 cells were treated with Sorafenib for 2 hours and then cells 
were harvested for protein and analyzed by Western blot for HER2 pathway targets. D, 
NT2.5 cells were treated with 5M and 10M Sorafenib or MAPK inhibitors for 6-7 hours 
and then cells were harvested for protein and analyzed by Western blot for cyclin 
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Figure 2: Sorafenib inhibits growth of breast cancer cells in vivo.  
A and B, FVB/N mice (n=10) were tumor challenged at Day 0 and began Sorafenib 
treatment on Day 14 and followed for tumor growth and overall survival.  Tumors were 
harvested at day 12 post-treatment and formalin fixed and paraffin embedded and stained 
by immunohistochemistry.    Representative samples of mice treated with vehicle (top) or 
sorafenib (bottom) are shown with H&E staining or immunohistochemistry to detect 
endothelial cells (PECAM/CD31), C, or apoptotic cells (activated caspase 3), D, at 10X 
magnification.   Staining was quantified using Elements software.  Graphs (mean + SD) 
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Figure 3: T cells are required for Sorafenib targeting of NT2.5 cells.  
A, the experiment in Fig. 2A was repeated in the setting of immune cell depletion.  Prior 
to beginning Sorafenib, NK cells or macrophages (Sor-NK, Sor-Mac) were depleted or C, 
CD4+ or CD8+ T cells (Sor-CD4, Sor-CD8) were depleted alone or together (Sor-
CD4/CD8) and followed for tumor growth and, B and D,  overall survival.  E, in a separate 
experiment, FVB/N (n=6) were tumor challenged treated with Sorafenib treated or vehicle 
control until the Sorafenib treated tumors had completely regressed, upon which point the 
vehicle group was sacrificed and the Sorafenib treatment ceased.  After 1 week mice were 
re-challenged on the contralateral side and followed for tumor growth at the original site 
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The data presented here support two new findings.  First, the tyrosine kinase inhibitor 
Sorafenib inhibits the growth of breast cancer cells in vitro and in vivo by both MAPK 
dependent and independent mechanisms.  Second, Sorafenib-induced tumor rejection is, in 
part, T cell-mediated.  Both CD4+ and CD8+ T cells are required for tumor regression with 
single agent Sorafenib treatment.   Additionally, treatment with Sorafenib supports the 
development of immunological memory, preventing the outgrowth of a tumor challenge.  
Although many studies have investigated the effect of Sorafenib on immune cells, this is 
the first study showing immune cell dependence for drug efficacy. 
Given the multiple components of the dynamic host-tumor cell interactions within the 
tumor microenvironment, therapies successfully targeting multiple pathways will likely 
result in the most effective treatments.   Here, it is demonstrated that Sorafenib inhibits the 
growth of HER-2-overexpressing breast tumors by a variety of mechanisms, including 
inhibition of cell growth, induction of cell death, and inhibition of angiogenesis.  In vitro, 
clinically relevant concentrations of Sorafenib (5μM-10μM) induced marked inhibition of 
cell growth.  Additionally, Sorafenib inhibited MAPK signaling in NT2.5 cells, likely 
resulting in decreased cell growth and increased cell death.  These data are consistent with 
reported effects of Sorafenib on the Ras/MEK/ERK pathway in other cancer models 14,24-
28.  These findings were extended to show that decreased expression of the MAPK 
downstream target, cyclin D1, was greatest with Sorafenib treatment compared to treatment 
with inhibitors specific for either p38 MAPK or ERK MAPK.   Unlike individual p38 
MAPK or ERK MAPK inhibitors, Sorafenib treatment also decreased cyclin D3 
expression.  These findings suggest that Sorafenib also targets MAPK independent 
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pathways essential for cell cycle progression and proliferation, and is consistent with 
previously published reports showing that cyclin D1 and cyclin D3 are differentially 
regulated23.  Therapies targeting both cyclins will likely be most effective at inhibiting cell 
growth and successfully decreasing breast tumor burden.29.  In support of this, Sorafenib 
treatment resulted in a significant increase in cell death by increase in apoptotic cell 
markers in vitro.  
In vivo, Sorafenib has been shown to inhibit tumor growth in numerous murine cancer 
models30.  Here, it is shown that daily Sorafenib treatment enhanced tumor clearance in 
FVB/N mice implanted with HER-2-overexpressing NT2.5 tumors.  Sorafenib mediated 
tumor destruction through inducing cell death through apoptosis, as reflected by increased 
staining of activated caspase 3 in Sorafenib treated tumors.  In addition to its direct tumor 
cell cytotoxicity, Sorafenib potently inhibits angiogenesis in NT2.5 tumors.  Sorafenib 
treated tumors displayed substantial reduction in the number of CD31/PECAM positive 
microvessels, consistent with reported anti-angiogenic effects of the drug14.   
In addition to its direct anti-angiogenic and cytotoxic effects, these data demonstrate that 
Sorafenib requires T cells to mediate durable anti-tumor activity. Simultaneously removing 
both CD4+ and CD8+ T cells completely abrogated the therapeutic effect of Sorafenib.  
Additionally, Sorafenib treatment protected mice from tumor growth after re-challenge, 
demonstrating immunologic memory effect.  While several studies have reported on the 
impact of Sorafenib on the immune system18,20,21,31-33, this is the first study showing a direct 
T cell- dependent mechanism of action for Sorafenib-mediated tumor clearance.   These 
data build upon previously published work illustrating the influence of the immune system, 
specifically T cells, on the activity of anti-angiogenic therapies.  Additionally, Sorafenib 
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can elicit long-lasting systemic immunity reflected by rejection of a second tumor 
challenge.  Re-growth was observed in a few of the original tumors once treatment ceased.  
This demonstrates the dynamic immune resistance mechanisms that are active within the 
tumor microenvironment and suggests that it may be advantageous to combine other 
immune-modulating therapies with Sorafenib to enhance therapeutic benefit in patients.  
Angiogenesis causes the formation of abnormal vascular networks resulting in hypoxia, 
increased tumor pressure, and acidosis within the tumor microenvironment.  These 
conditions activate anti-inflammatory signals within the tumor microenvironment that 
support the recruitment of suppressive immune cell populations subsequently inhibiting 
effector cell activation.  Resultant impaired APC cell maturation and migration and 
impaired T cell trafficking and activation dampens productive anti-tumor responses34.  
Therefore, inhibiting angiogenesis may work to remodel the tumor microenvironment to 
one that is more immunosupportive rather than immunosuppressive34-36.   
Given the established clinical indications for Sorafenib and the complex immune effects 
reported on Sorafenib, further studies are necessary to elucidate the T cell-dependent 
mechanism of Sorafenib.  The later chapters of this thesis explore the effects of Sorafenib 
on two important immune cell types within the breast tumor microenvironment, T cells and 
TAMs.  The final chapter will address these immune mechanisms in the context of using 
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Chapter 3: The Immunomodulatory Effects of Sorafenib on T cells 
Introduction: 
Anti-tumor responses mediated by T cells are essential for successful tumor cell 
destruction.  Antigen-targeted CTLs can exit the thymus and may be able to recognize 
altered self-antigens that are present on the tumor.  However, peripheral immune tolerance 
and escape mechanisms active within the tumor microenvironment often result in impaired 
T cell function such as reduced cytokine production as well as hypo-responsiveness to 
antigenic re-stimulation1,2.  
In addition to overall decreased T effector cell function within the tumor, the presence of 
Tregs characterized by the expression of FoxP3 can also hinder productive effector T cell 
(Teff) responses.  Tregs are a subset of CD4+ T cells that are specialized in suppressing T 
cell proliferation through the production of cytokines such as IL-10 and TGF.  Under 
normal conditions, Tregs represent up to 5% to 10% of peripheral CD4+ T cells and are 
responsible for maintaining and controlling immunological self-tolerance4.  Increased 
peripheral blood CD4+ CD25+ Tregs have been reported in breast cancer patients 5. 
In addition to its cytotoxic and anti-angiogenic properties, the TKI, Sorafenib, has been 
reported to have T cell-modulating activity.  For example, RCC patients receiving 
Sorafenib treatment were reported to have decreased tumor-promoting T regulatory cells 
in peripheral blood as well as within the tumor, resulting in increased Teff responses.  Low 
doses of Sorafenib have been shown to increase Teff proliferation and IL-2 secretion in 
vitro and induce a Th1 dominant response in vivo in patients with HCC6-8.  Conversely, 
studies have also shown that Sorafenib may inhibit T cell responses through inhibiting 
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peripheral T cell proliferation and altering LCK phosphorylation9.  Reports also show a 
decrease in antigen specific T cell responses with Sorafenib treatment10.  It is unknown 
whether or not these immune modulating effects are present during Sorafenib treatment of 
breast cancer. 
In Chapter 2, it was demonstrated that Sorafenib treatment is effective as a single agent in 
enhancing tumor resolution in FVB/N mice with orthotopically implanted NT2.5 
mammary tumors.  Additionally, depletion studies showed the mechanism of Sorafenib is, 
at least in part, dependent on the presence of both CD4+ and CD8+ T cells (Ch2, Figure 
3A & 3B).  These studies aim to determine the effect of Sorafenib on both effector and 
regulatory T cells using both in vitro and in vivo murine models of HER2 over-expressing 
breast tumors. 
It was hypothesized that Sorafenib would augment anti-tumor effector T cell responses to 
promote tumor clearance.  To address this hypothesis, the effects of Sorafenib on CD4+ 
and CD8+ T cells in vitro were characterized.   The effect of Sorafenib on Teff and Treg 
activation, proliferation, and cytokine production was also examined.  The effect of 
Sorafenib on Th1 cell cytokine production specifically was examined. Finally, the effect 
of Sorafenib on tumor infiltrating T cells in vivo was analyzed.  While in vitro studies 
suggest that Sorafenib inhibits T cell proliferation and cytokine secretion, in vivo data does 
not corroborate these results.  Therefore, the environments in which experiments are 
carried out are an important factor in evaluating the effect of Sorafenib on immune cells, 
specifically T cells.  These results reiterate the complexities of the cellular interactions 
within the tumor microenvironment and suggest that there may be other, yet undetermined, 
immune mechanisms of Sorafenib-mediated tumor clearance.        
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Materials and Methods: 
Mice 
FVB/N mice were purchased from Harlan (Frederick, MD). FVB/N FoxP3-GFP mice were 
maintained in house. OT-1 OVA TCR transgenic mice and 6.5 HA-TCR transgenic mice 
were donated from the laboratory of Dr. Charles Drake at Johns Hopkins School of 
Medicine.  Experiments were done with 8 to 12 week old mice.  Animals were housed in 
pathogen-free conditions and were treated in accordance with institutional and AAALAC 
policies. All protocols were approved by the Animal Care and Use Committee of Johns 
Hopkins University. 
Reagents 
Sorafenib was purchased from LC Laboratories (Woburn, MA). CD4 Pacific Blue, CD8 
FITC, FoxP3 PE, CD25 PE, IFNg-PeCy7, IL-17 Percp5.5, TNF AF700, IL-2 APC, Tbet 
PE  antibodies were obtained from eBioscience. Dynabeads Mouse T-Activator 
CD3/CD28 for T-Cell Expansion and Activation (Anti-CD3/anti-CD28 beads) and 
Carboxyfluorescein succinimidyl ester (CFSE) were purchased from Life Technologies.  
Human recombinant IL-2 was purchased from R&D Systems.  Mouse recombinant soluble 
anti-mouse CD3 and CD28, and mouse recombinant IFN, IL-2 and IL-12 were donated 
by the laboratory of Dr. Jonathon Powell at Johns Hopkins School of Medicine. OVA and 
HA peptides were donated by the laboratory of Dr. Charles Drake at Johns Hopkins School 
of Medicine. 
Cell Lines and Media 
The NT2.5 tumor cell line, derived from a spontaneous tumor of a neu-N transgenic mouse, 
was grown as previously described11. 
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Antigen Specific T Cell Proliferation Assays 
Splenic CD8+ T cells from OT-1 mice or CD4+ T cells from HA transgenic mice were 
isolated by negative isolation following the package instructions (Dynabeads, Life 
Technologies).  Cells were labeled with CFSE as per package instructions and cells were 
plated in 96 well at 106 cells/ml with 20ng/l IL-2 in the presence or absence of 1ng/ml of 
peptide (OVA, CD8+ T cells and HA, CD4+ T cells) in the presence or absence of 0.1uM, 
1uM, or 10uM Sorafenib.  Control wells contained equivalent amounts of DMSO.  Cells 
were incubated at 37oC for 3 days and samples were run on Beckman Coulter Galios Flow 
Cytometer to analyze CFSE incorporation.  7-AAD was used to stain for live cells and 
analysis was performed on live cells based on 7-AAD negativity.  For CD8+ T cell assays, 
half of the cells were fixed and permeabilized with FoxP3- staining buffer set (eBioscience) 
and stained with IFN APC.   
Th1 skewing experiments 
3g/ml anti-CD3 in PBS was added to 6 well plates and incubated for 2 hours at 37oC.  
Splenic CD4+ T cells were negatively isolated from FVB/N mice using Dynabeads No 
Touch CD4+ T cell isolation kit (Invitrogen).  2 × 105 cells were placed in each well of a 
96 well plate.  IFNIL-12 and IL-2 were added to induce Th1 cytokine production.  All 
wells received 2g/ml soluble anti-mouse CD28.  Sorafenib treated wells received 8M 
Sorafenib.  The amount of DMSO was normalized for all wells in the experiment.  Cells 
were incubated at 37oC for 3 days and cells were stained for CD4 and fixed and 
permeabilized with FoxP3 Staining Buffer Kit (eBioscience) and stained for IL-2 APC, 
IFN PECy7, TNF AF700, and Tbet PE and run on Beckman Coulter Galios Flow 
Cytometer.  Results were analyzed using FlowJo Analysis software. 
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Treg proliferation Experiments 
Splenic CD4+ T cells from FVB/N-FoxP3-GFP were isolated by negative isolation.  
FoxP3+GFP+ cells (Tregs) were sorted using Cell Sorting Facility at Johns Hopkins School 
of Medicine.  CD4+ FoxP3- cells (Teff) were also collected.  Cells were labeled with Cell 
Proliferation Dye eFluor® 670 (Ebioscience) and 105 Tregs or Teff were plated in the 
presence of 4M or 8M Sorafenib with anti-CD3/anti-CD28 beads and 30U/ml rIL-2.  
The amount of DMSO was normalized for all wells in the experiment.  Separately, 2×105 
cells were plated in triplicate for overnight culture without anti-CD3/anti-CD28 stimulation 
for analysis of surface marker staining of FoxP3 and CD25.  After 3 days, stimulation at 
37oC, the cells were stained for surface CD4 and CD4+ FoxP3+ cells were analyzed for 
proliferation by running samples on the Beckman Coulter Galios Flow Cytometer. 
Treg Suppression Assay 
Splenic CD4+ T cell were isolated from FVB/N mice by negative isolation.  Tregs were 
then selected for using CD4+CD25+ Regulatory T Cell Isolation Kit (MACs Miltenyi 
Biotec).  Tregs were treated for 24 hours with 0mM, 0.1M, 1M, or 10M Sorafenib.  
The following day CD4+ Teff were isolated from the spleens of FVB/N mice by negative 
isolation.  Teffs were labeled with CFSE.  Sorafenib was removed from Treg cultures and 
cells were washed with serum-free media and 105 Teff cells were plated with the following 
ratio Teff: Treg: 1:0, 1:1, 2:1, and 5:1 in the presence 0.5l anti-CD3/anti-CD28 beads.  
This amount was experimentally determined to be appropriate to allow suppression of 
proliferation in the presence of Treg cells at a 1:1 ratio of Tregs to Teffs. Teffs were 




Tumor-infiltrating T cell analysis 
FVB/N mice were challenged subcutaneously with 5×106 NT2.5 tumor cells in the right 
mammary fat pad, followed by treatment 10-14 days later.  Sorafenib (30mg/kg) was 
administered in 100μl daily Monday through Friday by oral gavage with a feeding needle. 
A viscous vehicle composed of 30% (w/v) Cremophor EL, 30% (w/v) PEG 400, and 10% 
ethanol, 10% glucose (Sigma-Aldrich) was used both to dissolve Sorafenib and 
administered as the vehicle treatment control. Mice were monitored for tumor growth and 
onset twice weekly. Tumor growth was determined by measuring tumor diameter in two 
perpendicular dimensions with calipers Mice were treated for 12 days and then tumors and 
spleens were harvested.  At this time point, there was a statistically significant difference 
in tumor size between vehicle and Sorafenib treated tumors (Chapter 2, Figure 3A & 3B).  
Tumors were digested with Liberase TM (Roche) for 30 minutes and the single cell 
suspension was stained for CD4 and CD8 and then fixed and permeabilized and stained for 
intracellular IL2, IFN, FoxP3, IL17, and TNFeBioscience) and run on the Beckman 
Coulter Galios Flow Cytometer.  Results were analyzed with FlowJo analysis software. 
Statistical Analysis 
Statistical analysis was conducted either in Microsoft Excel or GraphPad Software using 
an unpaired, two-tailed Student’s t-test, assuming equal population variances to determine 





Sorafenib inhibits antigen specific T cell proliferation in vitro 
In order to determine potential immunomodulatory effect of Sorafenib on T cells, the effect 
of Sorafenib on T cell proliferation, cytokine production, and function in vitro was 
examined.  OT-1 splenic CD8+ T cells pulsed with OVA peptide were used to analyze 
antigen-specific CD8+ T cells as it is a well-established model of antigen-specific CD8+ 
T cell proliferation and it has been previously used to study the effect of Sorafenib on T 
cell proliferation in vitro10,12.   There was a concentration dependent decrease in the amount 
of OVA-specific CD8+ T cell proliferation with increasing concentrations of Sorafenib 
(Figure 4A). Sorafenib treatment also resulted in a decrease in proliferation of CD8+ T 
cells in culture in the absence of peptide.  IFN production by CD8+ T pulsed with OVA 
peptide also decreased with Sorafenib treatment (Figure 4B).   
To analyze antigen-specific CD4+ T cell responses, HA-specific T cell responses were 
measured in 6.5 splenic CD4+ T cells.  This model is a well-established model of antigen-
specific CD4+ T cell proliferation in vitro13.  High concentrations of Sorafenib resulted in 
decreased proliferation in CD4+ T cells pulsed with HA peptide (Figure 4C).  Taken 
together, these data confirm previous studies that Sorafenib can impair T cell proliferation 
in vitro6,9,10.       
Sorafenib inhibits cytokine production of Th1 CD4+ T cells in vitro  
Productive anti-tumor immune responses usually coincide with a Th1-type immune 
response, indicated by the presence of Th1- CD4+ T helper cells that secrete pro-
inflammatory cytokines such as IFN, TNF, IL-2, and lymphotoxin14.  Therefore, the 
65 
 
ability of Sorafenib to promote the production of Th1 cytokines, TNF, IL-2, and IFN in 
CD4+ T cells was examined in vitro.  CD4+ T cells in the presence of Th1 cytokines and 
soluble CD28 showed increased IFN when compared to control cells that received 
soluble CD28 alone.  Treatment of splenic CD4+ T cells with Th1 skewing cytokines and 
soluble CD28 in the presence of Sorafenib resulted in decreased production of TNF, IL-
2, and IFN  Specifically, IFNproduction decreased from 35% to 15% with Sorafenib 
treatment.   CD4+ T cells that received only CD28 alone displayed increased TNF and IL-
2 production when compared to cells treated with Th1 skewing cytokines in the presence 
of Sorafenib. (Figure 5A-5C).  The effect of Sorafenib treatment on Tbet, the master-
regulator transcription factor of Th1 cell fates, was also analyzed (Figure 5D).  Treatment 
with Sorafenib did not alter Tbet expression in the CD4+ T cells in the presence of Th1 
cytokines and soluble CD28.  
Sorafenib alters the proliferation, activation, and function of Tregs in vitro   
Reduction in number or function of suppressive Treg populations can result in enhanced T 
cell-mediated tumor clearance.  Preferentially targeting Tregs, leaving effector cell 
populations unharmed, have been shown to be an effective mechanism to improve anti-
tumor immunity in Sorafenib- treated HCC patients8.  Therefore, the ability of Sorafenib 
to target CD4+ Treg proliferation was explored in vitro.  Sorafenib treatment of splenic 
CD4+ FoxP3+Tregs resulted in decreased cell proliferation in response to TCR stimulus 
with CD3/ CD28 beads.   A decrease in proliferation was similarly observed in CD4+ 
FoxP3- T effector cells treated with Sorafenib (Figure 6A).  Taken together, these data 
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indicate that in vitro treatment of CD4+ T cells with Sorafenib results in diminished cell 
proliferation, irrespective of cell function.   
Phenotypic markers CD25 and FoxP3 have been shown to correlate with the suppressive 
capacity of Tregs15,16.   Therefore, the effect of Sorafenib treatment on the expression of 
CD25 and FoxP3 in Tregs was also analyzed.  The percentage of CD25+ FoxP3+ Tregs 
was largely unchanged after 24 hours treatment with Sorafenib (Figure 6B & 6C).  
However, increasing concentrations of Sorafenib did cause a significant decrease in 
relative expression of both CD25 and FoxP3 measured by decreased mean fluorescence 
intensity by flow cytometry analysis (Figure 6D & 6E).   
To further examine if the observed decrease in these Treg phenotypic markers 
corresponded to altered Treg suppressive activity in this system, Sorafenib-treated Tregs 
were analyzed for suppressive function in vitro.  Tregs were treated with Sorafenib 24 
hours prior to the addition of CFSE-labeled CD4+ effector cells (Teff) at increasing cell 
ratios of Tregs to effector cells.  At lower Treg to Teff cell ratios (1:5), higher 
concentrations of Sorafenib significantly decreased the suppressive capacity of Tregs in 
culture compared to untreated Tregs as evidenced by increased CD4+ effector T cell 
proliferation at these ratios(Figure 6F).  Taken together, these data indicate that Sorafenib 
decreased the proliferation and activation of Tregs in vitro as well as decreased their 
suppressive capacity at physiological Treg to Teff cell ratios.  However, Sorafenib is not 





Sorafenib does not affect infiltration or cytokine production of TILs 
The effect of Sorafenib on tumor-infiltrating T cells (TILs) was then examined.  TILs from 
NT2.5 tumors in FVB/N mice treated with Sorafenib or vehicle control were analyzed by 
flow cytometry.  TILs isolated from tumors of Sorafenib-treated mice and vehicle treated 
mice showed a relatively similar composition of both CD8+ T cells and CD4+ T cells.  
Intracellular staining showed no differences in the cytokine profiles of CD8+ or CD4+ T 
cells. Finally, there was no difference in the percentage of CD4+FoxP3+ T cells infiltrating 





Figure 4: Sorafenib inhibits antigen specific T cell proliferation and cytokine 
production in vitro.   
A, Proliferation of CFSE-labeled splenic CD8+ from OT-1 transgenic mice in response to 
OVA peptide stimulation for 3 days in the presence or absence of Sorafenib.  B, IFN 
production of the CD8+ T cells from A.  C, Proliferation of CD4+ T cells from 6.5 
transgenic mice in response to HA peptide stimulation for 3 days in the presence of 











































































































































































Figure 5: Sorafenib inhibits cytokine production of Th1-skewed cells in vitro 
FVB/N splenic CD4+ T cells were negatively isolated and plated at with or without Th1-
skewing cytokines IFN, IL-12 and IL-2 in the presence of 2g/ml soluble anti-mouse 
CD28 and plate-bound anti-mouse CD3.  Sorafenib treated wells received 8M Sorafenib.  
After 3 days cells were analyzed by ICS for IFNA, TNF, B, and IL-2, C.  Tbet levels, 
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Figure 6: Sorafenib alters the proliferation, activation, and function of Tregs in vitro 
A, Splenic FoxP3+GFP+ CD4+ T cells (Tregs) and CD4+ FoxP3-  CD4+ T cells (Teff) 
were collected.    105 Tregs or Teff were plated in the presence of 4M or 8M Sorafenib 
with 0.5l anti-CD3/anti-CD28 beads and proliferation was analyzed after 3 days in 
culture.  B, 2×105 FoxP3+GFP+ CD4+ cells were plated in triplicate for overnight culture 
with Sorafenib and stained for surface markers FoxP3 and CD25.  Relative expression of 
FoxP3, C, and CD25, D, was also analyzed. CD4+ CD25+ cells were used as Tregs and 
treated overnight in culture with 0M, 0.1M, 1M, and 10M Sorafenib.  After 24 hours, 
CD4+ Teff were isolated and were labeled with CFSE.  Sorafenib was removed from Treg 
cultures and Teff cells were plated at the following ratios of Treg:Teff, with 105 Teff 
staying constant: 0:1, 1:1, 1:2, and 1:5 in the presence of 0.5l of anti-CD3/anti-CD28 
beads.  E, Proliferation was analyzed after 3 days by CFSE incorporation in Teffs. *, P < 
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Figure 7: Sorafenib does not alter tumor-infiltrating T cell number or cytokine 
production in vivo 
FVB/N mice were challenged subcutaneously with 5×106 NT2.5 tumor cells.  After 10 
days, mice were treated with Sorafenib (30mg/kg) for 12 days and then tumors were 
harvested and digested.  Single cell suspension was stained for A, CD4 and B, CD8 and 
then fixed and permeabilized and stained for intracellular , IFN,  C and F, TNFD and 
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The data presented here confirm previous findings that Sorafenib inhibits T cell 
proliferation and cytokine production in vitro.  Additionally, these data expand upon 
previous studies,  elucidating a potential mechanism by which Sorafenib may inhibit Tregs 
in vitro through alterations in activation markers, CD25 and FoxP3, decreasing suppressor 
function.  Lastly, these data support a new finding that, in contrast to in vitro observations, 
Sorafenib treatment does not inhibit T cell infiltration or cytokine production at the tumor 
site in vivo.  
The ability of Sorafenib to inhibit T cells has been well documented.  In 2008, Hipp et al. 
showed inhibition of OVA-specific CD8+ T cell responses in vivo in mice pre-treated with 
Sorafenib followed by peptide vaccination with adjuvant10.  In the same year, W. Zhoa and 
colleagues published that off target effects of Sorafenib target LCK phosphorylation, 
thereby inhibiting the activation of human peripheral T cells9.  In 2009, R. Houben and 
colleagues showed a decrease in survivin-specific T cell responses in melanoma patients 
vaccinated against survivin with Sorafenib treatment6.  In Chapter 2, it was reported that 
Sorafenib treatment augmented NT2.5 tumor clearance in FVB/N mice by a T cell-
dependent mechanism.  Given the myriad proposed T cell effects potentiated by Sorafenib, 
it was necessary to evaluate the in vitro and in vivo effects of Sorafenib in this model 
system. 
The previously published OT-1-OVA system and 6.5-HA system were used to analyze in 
vitro effects of Sorafenib on T cell proliferation.  Both antigen specific CD8+ and CD4+ T 
cells showed decrease in proliferation in response to peptide with Sorafenib treatment.  
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CD8+ IFN production also decreased in the presence of Sorafenib.  These data are 
consistent with prior studies demonstrating that Sorafenib decreased T cell proliferation 
and cytokine production in vitro6,9,10. The data presented here also expands upon these 
studies to analyze the effect of Sorafenib specifically on Th1 cytokine production. While 
Sorafenib treatment decreased the production of Th1 cytokines, specifically, IFN
does not affect the expression of Tbet.  This suggests that Sorafenib may not be 
permanently affecting licensing of CD4+ T cells to become Th1 cells, however this remains 
unknown.    
Conversely, several groups have shown a positive impact of Sorafenib treatment through 
modulating T regulatory cells both in mice and humans 7,8,17-19.   In HCC patients receiving 
Sorafenib therapy, decreased peripheral Tregs corresponded to increased clinical benefit18.    
The in vitro data  presented here support these previous findings showing that Sorafenib 
can decrease Treg proliferation, phenotypic activation markers, and function.   In vitro, 
Sorafenib inhibits proliferation and significantly decreases the expression of CD25 and 
FoxP3 on Tregs.  This decrease in expression of activation marker corresponds to a 
decrease in suppressive function.  At physiologically relevant cell ratios of Treg to Teff, 
Sorafenib treatment results in a significant decrease in the ability of Tregs to suppressive 
the proliferation of CD4+ T effector cells.  It is also possible that at lower ratios of 
Tregs:Teff, Sorafenib pre-treatment of Tregs altered cell viability, therefore, these results 
may also be explained by a diminished number of Tregs rather than decreased suppressive 
capacity.  This could be reconciled in the future by verifying the viability of the Tregs at 
the assay endpoint.         
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In contrast to in vitro observations, in vivo, there were no differences between the absolute 
numbers of infiltrating T cells, nor were there measurable differences in the cytokine 
profiles of CD4+ or CD8+ T cells as a result of Sorafenib treatment.  Sorafenib treatment 
does not inhibit T cell alter trafficking of T cells to the tumor, nor does it modify cytokine 
production by T cells at the tumor site.  Additionally, there were no differences in the 
number of tumor-infiltrating FoxP3+ T cells, contrasting reports published in HCC18,19.  It 
remains unknown as to whether Sorafenib treatment affects the function of tumor-
infiltrating Tregs in vivo.   
Mounting a successful immune response within the tumor microenvironment is complex, 
the mechanisms of which are still under active investigation.  Immune-mediated tumor 
clearance relies on the ability of effector T cells to enter the tumor, secrete cytokines and 
actively kill tumor cells.  According to the data presented here, Sorafenib does not improve 
T cell infiltration into the tumor nor does it enhance cytokine production by effector cells.  
Additionally, it does not reduce the percentage of suppressive Treg at the tumor site.  
However, the effect of Sorafenib on other effector functions of the infiltrating cells besides 
cytokine secretion, such as killing, remains unknown.   Additionally, it is possible that 
Sorafenib may be targeting other cells within the tumor to enhance clearance by T cells.  
For example, Sorafenib-mediated tumor cell death may elicit increased danger signals to 
promote enhanced tumor clearance20,21.  Additionally, Sorafenib may be altering co-
stimulatory molecules to augment recognition of the tumor22.  Also, Sorafenib treatment 
may induce changes within antigen presenting cells in the tumor microenvironment,  
allowing for improved priming and increased antigen presentation within the tumor.  To 
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Chapter 4: The Immunomodulatory Effects of Sorafenib on Tumor-associated 
Macrophages 
Introduction: 
Macrophages are mononuclear phagocytes of the innate immune system that defend the 
host against harmful pathogens and heal tissues after injury.  Macrophages also regulate 
tissue growth, homeostasis and repair through the expression and release of a variety of 
growth factors and cytokines.  Macrophages phagocytose microbes and present antigens to 
T cells, orchestrating the acute inflammatory response to eliminate the invading pathogens 
1.  Additionally, macrophages play a role as scavengers that clear tissue debris.    Given 
their diverse function, macrophages play a central role in inflammation, tissue remodeling, 
cell growth and angiogenesis; many of these roles are known to promote tumor progression 
2,3.      
Macrophages are grouped into subsets based on the acquisition of distinct morphological 
and functional properties directed by particular tissues or immunological 
microenvironment 4,5.  Classically activated inflammatory macrophages (M1) are induced 
by IFNγ alone or combined with microbial stimuli, such as lipopolysaccharide (LPS), or 
with other cytokines such as TNF and GM-CSF.  These cells have an IL-12high, IL-23high, 
IL-10low phenotype
 6.  Moreover, these cells are also efficient producers of effector 
molecules such as reactive oxygen and nitrogen intermediates and inflammatory cytokines 
such as IL-1β, TNF and IL-6.  Consistent with these functional characteristics, M1 
macrophages participate in Th1 responses and help mediate resistance to intracellular 
infections and tumors 7.  
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In contrast, M2 or alternatively activated tissue tropic macrophages differentiate in 
microenvironments rich in Th2 cytokines such as IL-4 and IL-13 and in tissues to promote 
growth and development 8. These cells generally have high levels of scavenger, mannose, 
and galactose-type receptors 4.  Arginase expression is also increased as result in a shift in 
arginine metabolism to produce ornithine and polyamines.  In general, M2 cells participate 
in Th2 reactions, that promote killing and encapsulation of parasites, tissue repair, and 
remodeling 9-11. 
Lastly, a third subset of regulatory macrophages has been described.  Regulatory 
macrophages exhibit an IL-12low, IL-23low, IL-10high phenotype.  This results in the 
secretion of high levels of anti-inflammatory interleukin IL-10 and low levels of pro-
inflammatory IL-12/23. Prostaglandin E2 (PGE2), extracellular adenosine, immune 
complexes, VEGF, IL-10, and TGF-β, can all drive the regulatory macrophage phenotype 
12.  It has been shown that mitogen-activated protein kinase ERK plays a key role in this 
process 13-15. Under conditions of strong ERK activation, the anti-inflammatory cytokine 
IL-10 is upregulated and pro-inflammatory IL-12/23 is suppressed 16.   Because IL-10 can 
inhibit the production and activity of various pro-inflammatory cytokines, these regulatory 
macrophages are potent inhibitors of inflammation.   
Macrophages are a major cellular component of breast tumors, where they have been 
reported to compose as much as fifty percent of the infiltrating cells.  In the tumor, they 
are commonly termed tumor-associated macrophages (TAMs). These macrophages change 
their physiology and take on a phenotype that more closely resembles regulatory 
macrophages 17. The tumor-derived agents that induce the development of these regulatory 
macrophages have not been identified, but candidates include prostaglandins, hypoxia, 
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extracellular nucleotides, apoptotic cells, hyaluronan fragments and IgG 18-20, which may 
work synergistically within the tumor microenvironment. Irrespective of the stimulus, 
these tumor-associated macrophages produce high levels of IL-10, can inhibit immune 
responses to neo-antigens expressed by tumor cells, and can de-activate neighboring 
macrophages 21. Recent studies also suggest that regulatory macrophages can contribute to 
angiogenesis and thereby promote tumor growth 18. Clinical and experimental evidence has 
shown that cancer tissues with high infiltration of TAM are associated with poor patient 
prognosis and resistance to therapies 22.  There is also evidence that macrophage depletion 
in some cases may even be beneficial to the host  23. Given the role of TAMs in tumor 
progression, targeting of macrophages in tumors is considered a promising therapeutic 
strategy, whereby depletion of TAMs or their ‘re-education’ as anti-tumor effectors is 
under current investigation.  
Accumulating data suggest that, in addition to inhibiting tumor cell proliferation and 
angiogenesis, Sorafenib can modulate immune cell function, specifically macrophage 
function.   It has been previously shown that Sorafenib treatment can shift bone-marrow 
derived macrophages activated with LPS and PGE2 from the pro-tumorigenic IL-10 
secreting phenotype to the anti-tumor IL-12 secreting phenotype 24.  Additionally it was 
found that Sorafenib treatment enhances proinflammatory activity of TAMs and 
subsequently induces antitumor NK cell responses in a cytokine and NF-κB-dependent 
fashion. 25.  Conversely, in a murine HCC model Sorafenib treatment significantly 
increased peripheral recruitment and intratumoral infiltration of F4/80+CD11b+ cells and 
elevated pro-tumoral and pro-angiogenic factors in the tumor and peripheral blood, 
suggesting a role of macrophages in tumor progression under Sorafenib treatment.   
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Depletion of macrophages in combination with Sorafenib treatment significantly inhibited 
tumor progression, tumor angiogenesis, and metastasis compared with mice treated with 
Sorafenib alone.  Here, these studies are extended to explore the effect of Sorafenib on 
TAMs in a murine model of breast cancer.  
First, the impact of Sorafenib on TAM recruitment within the tumor was analyzed.  Then, 
the effect of Sorafenib treatment on TAM cytokine production was examined.  Finally, 
functional analysis on Sorafenib-treated TAMs was performed.  These data suggest that 
Sorafenib may alter the activation state of TAMs to increase pro-immunogenic cytokines 





Materials and Methods: 
Mice 
FVB/N mice were purchased from Harlan (Frederick, MD). Experiments were done with 
8 to 12 week old mice.  Animals were housed in pathogen-free conditions and were treated 
in accordance with institutional and AAALAC policies. All protocols were approved by 
the Animal Care and Use Committee of Johns Hopkins University. 
Reagents 
Sorafenib was purchased from LC Laboratories (Woburn, MA). CD11b FITC, MHCII PE, 
CD4 Pacific Blue, and CD8 Pacific Blue antibodies were obtained from eBioscience. 
Carboxyfluorescein succinimidyl ester (CFSE) were purchased from Life Technologies.  
Mouse recombinant soluble anti-mouse CD3 and CD28 were donated by the laboratory of 
Dr. Jonathon Powell at Johns Hopkins School of Medicine.  
Cell Lines and Media 
The NT2.5 tumor cell line, derived from a spontaneous tumor of a neu-N transgenic mouse, 
was grown as previously described 26. 
Drug treatment 
FVB/N mice were challenged subcutaneously with 5×106 NT2.5 tumor cells in the right 
mammary fat pad, followed by vaccination 10-14 days later.  Sorafenib (30mg/kg) was 
administered in 100μl daily Monday through Friday by oral gavage with a feeding needle 
beginning the day of vaccination. A viscous vehicle composed of 30% (w/v) Cremophor 
EL, 30% (w/v) PEG 400, and 10% ethanol, 10% glucose (Sigma-Aldrich) was used both 





Tumors harvested at day 12 post-treatment were fixed in formalin for 24 hours, paraffin-
embedded, and sectioned at 5uM by the JHMI Pathology Core.  Sections were stained with 
H&E or retained for immunohistochemistry at the JHMI Oncology Tissue Service Center.  
F480 was analyzed with antibodies specific for F480 (Cell Signaling).  Antigen retrieval 
was carried out for 45 minutes in HTTR steam (Target Retrieval Solution; Dako) followed 
by incubation with primary antibody for 45 minutes at room temperature.  Slides were 
incubated with Power Vision Poly-HRP anti-rabbit IgG secondary antibody for 30 minutes 
at room temperature. Slides were developed with 3, 3’ diaminobenzidine (Sigma Fast DAB 
tablets) and slides were counterstained with Mayers hematoxylin (Dako).  Images were 
captured under light microscopy at 20x magnification (E600, Nikon).   
Tumor-associated macrophage preparations 
Tumors were harvested day 12 post-treatment and suspended in 5 ml RPMI 1640 
containing Liberase TM (Roche).  Tumors were minced and incubated at 37°C for 30 min. 
Suspensions were then passed through a 100-μm mesh nylon cell strainer (BD Falcon) to 
obtain single cell suspensions. Single cell suspensions were incubated with in ACK lysing 
buffer (Sigma) for 2 min at room temperature and washed twice in FACS-staining buffer 
(PBS, 2% heat-inactivated FCS). Pellets were resuspended in FACs staining buffer 
containing Fc Block (MACs Miltenyi Biotec) and incubated on at 40C for 20 minutes.  
TAMs were incubated with FACs buffer containing biotinylated anti-F480 (eBioscience) 





104 TAMs were resuspended in 1ml PBS.   Cells were spun onto chambered microscope 
slides at maximum speed for 5 minutes.  Slides were allowed to dry and stained with Diff-
Quick, following the manufacturers instructions, to visualize morphology. 
Quantitative real-time PCR  
mRNA was extracted from T cells with TRIzol Reagent (Life Technologies) following the 
manufacturer’s protocol.  cDNA was synthesized with a RNA to cDNA with EcoDry 
Premix kit (Clontech).  All primers were purchased from Life Technologies-Applied 
Biosystems; reactions were performed in triplicate using an Applied Biosystems 
StepOnePlus Instrument. 
TAM Suppression Assay 
Splenic CD4+ T cells or CD8+ T cells were isolated from FVB/N mice by negative 
isolation.  Tregs were then selected from the CD4+ T cell population using CD4+CD25+ 
Regulatory T Cell Isolation Kit (MACs Miltenyi Biotec).  Tumors were harvested from 
FVB/N mice on day 12 post-treatment.  Tumors were minced and digested in Liberase TM 
(Roche) for 45 minutes.  Cells were filtered through 100M filters to obtain a single cell 
suspension.   Red blood cells were lysed using ACK lysis buffer (Sigma).  TAMs were 
isolated by positive selection for F480 using biotinylated anti- (MACs Miltenyi Biotec).  T 
cells were labeled with CFSE.  105 T cells were plated with the following ratio T cell: 
TAM: 1:0, 1:1, 2:1, and 5:1 in the presence 1g/ml of anti-CD3 2g/ml anti-CD28.  T cells 
were also plated with at a 1:1 ratio with Tregs as a suppression control for the assay.    T 





Statistical analysis was conducted either in Microsoft Excel or GraphPad Software using 
an unpaired, two-tailed Student’s t-test, assuming equal population variances to determine 




Sorafenib treated tumors seemed to show an increase in F480+ tumor-infiltrating 
macrophages with increased activation morphology 
First, the purity of TAMs isolated from tumor tissue had to be verified (Figure 8A-C).  
TAMs were obtained through F480+ isolation.  FACs analysis post-isolation showed a 
population of cells that were ninety percent CD11b+ and fifty percent positive for MHC 
class II.  Morphology of TAMs was confirmed by cytospin (Figure 8C). 
 The effect of Sorafenib treatment on TAM infiltration was analyzed by 
immunohistochemistry.   TAMs were isolated from the NT2.5 tumors that were implanted 
into FVB/N mice on day 12 post-treatment with Sorafenib or vehicle control.  This 
timepoint has been shown previously to result in tumor sizes that are significantly different 
between Sorafenib and vehicle treated mice (Chapter 2, Figure 2).  Tumors of Sorafenib 
treated mice showed an increase in F480+ cells by immunohistochemistry analysis (Figure 
9A).  Additionally, TAMs from Sorafenib treated tumors showed an increased in activated 
morphology upon analysis of cytospin compared to TAMs isolated from vehicle treated 
mice (Figure 9B).  
Sorafenib enhances M1 cytokine secretion in tumor-associated macrophages 
The effect of Sorafenib on the expression of macrophage polarity genes was then analyzed 
by qrt-PCR.  Qrt-PCR analysis of TAMs isolated from Sorafenib treated tumors showed 
an increase in expression of two M1 genes, IL-12 and IL-6, when compared to TAMs 
isolated from vehicle treated tumors (Figure 10A-D).   Sorafenib treatment also resulted in 
a modest increase in arg1 expression in TAMs (Figure 10E).  IL-10 expression, a marker 
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of regulatory macrophages, was decreased in TAMs isolated from Sorafenib treated tumors 
compared with the vehicle control (Figure 10F).   
Sorafenib treated macrophages increase CD4+ T cell activation 
To determine if the observed changes in cytokine gene expression corresponded to altered 
function, the effect of Sorafenib treatment on TAM suppressive function was then 
analyzed.  Increasing ratio of TAMs from Sorafenib-treated tumors resulted in increased 
CD4+ T cell proliferation in response to CD3/CD28 stimulus compared to vehicle 
control TAMs and CD4+ T cells cultured in the absence of TAMs (Figure 11A). TAMs 
from vehicle treated tumors suppressed CD4+ T cell proliferation at all cell ratios.  
However, TAMs do not seem to suppress CD8+ T cell proliferation (Figure 11B).  The 
presence of TAMs from either vehicle-treated or Sorafenib-treated tumors resulted in 




Figure 8: Schema for Macrophages isolation from FVB/N tumors.  A, Splenocytes were 
isolated from an FVB/N tumor bearing mouse and analyzed by flow cytometry for CD11b 
and MHC class II as a staining control for macrophages isolated from tumors.  B, F480+ 
isolated TAMs were stained for Cd11b and MHC class II.  C, Cytospin of F480+ cells was 



























Figure 9: Sorafenib treatment increased F480+ cells in the tumor and alters TAM 
morphology. Tumors were harvested at day 12 post-treatment and formalin fixed and 
paraffin embedded and stained by immunohistochemistry for F480.    Representative 
samples of mice treated with vehicle, A, or Sorafenib, B, are shown at 20X magnification.  
F480+ were cells were isolated from tumors at day 12-post treatment and cytospins were 
performed on 104 F480+ TAMs from the tumors of vehicle, C, or Sorafenib, D, treated 
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Figure 10:  Sorafenib treatment enhances M1 cytokine expression in TAMs.  Cytokine 
gene expression to analyze macrophage polarity in F480+ TAMs isolated from tumors of 
vehicle (white bars) or Sorafenib (black bars) treated mice was performed by qrt-PCR. M1 
markers IL-12, A, IL-1, B, iNOS, C, and IL-6, D, were by analyzed.  M2 marker, arg1, 
E, was analyzed.  Regulatory marker, IL-10, F, was analyzed. 
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Figure 11: TAMs from Sorafenib treated tumors enhance CD4+ T cell proliferation. 
A, F480+ TAMs were isolated from tumors of vehicle (white bar) or Sorafenib (black bar) 
treated mice.  Splenic CD4+ T cells were isolated and labeled with CFSE. 105 CD4+ T 
cells were plated in the presence of TAMs at the following cell ratios, with 105 T cells 
staying constant: 0:1 (blue bar-Proliferation control), 1:1, 1:2, and 1:5 in the presence of 
0.5l of anti-CD3/anti-CD28 beads. Proliferation was analyzed after 3 days by CFSE 
incorporation in CD4+ T cells.  Tregs (gray bar) were also isolated and plated with CD4+ 
T cells as a suppression control for the assay, *, P< 0.05, ***, P < 0.001.  B, the experiment 




























































The present study supports three new findings.  First, the tyrosine kinase inhibitor, 
Sorafenib, induces increased infiltration of F480+ TAMs into NT2.5 tumors implanted into 
FVB/N mice.   Second, Sorafenib is able to alter cytokine expression of TAMs to increase 
IL-12 and decrease IL-10.  Lastly, Sorafenib treated TAMs may enhance the proliferation 
of CD4+ T cells.   
Studies have reported on the role of TAMs in tumor progression, therefore, therapies that 
can target TAMs may prove to have a therapeutic benefit.  Sorafenib has been reported to 
increase the recruitment of TAMs into the peripheral blood of HCC patients. The data 
shown here agrees with the previous reports, showing an increase infiltration of F480+ 
TAMs in the tumor of FVB/N mice treated with Sorafenib. 
However, in contrast to previous data, prt-PCR of inflammatory cytokine shows that while 
TAMs from vehicle treated mice have a regulatory phenotype (IL-10 hi IL-12 low), 
Sorafenib treatment alters this gene expression to resemble classically activated 
macrophages (IL-12 high and IL-10 low).  Therefore, macrophages that enter the tumor in 
Sorafenib treated mice may be playing a beneficial role in supporting tumor clearance 
through enhanced secretion of pro-inflammatory cytokines.  Edwards, et al, has previously 
published on the ability of Sorafenib to skew bone marrow derived macrophages in vitro 
24.  These data support these findings and extend them to include macrophages within the 
tumor. 
Additionally, functional analysis of TAMs shows in the absence of Sorafenib, vehicle 
treated TAMs suppress CD4+ T cell proliferation, supporting the suppressive nature of 
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regulatory macrophages within the microenvironment of breast tumors.  Treatment with 
Sorafenib enhanced the ability of TAMs to stimulate CD4+ T cell proliferation.  TAMs 
isolated from the tumors of both treatment groups equally enhanced CD8+ T cell 
proliferation.  This may be explained by the strength of CD3/CD28 stimulus on inducing 
CD8+ T cell proliferation.  Alternatively, this data may indicate that antigen presentation 
on MHC class I molecules remains unhindered on TAMs to promote CD8+ T cell 
proliferation.  However, inhibitory interactions between macrophages and CD4+ T cells 
within the tumor microenvironment may prevent necessary T cell help to sustain CD8+ T 
cell proliferation.  The induction of pro-inflammatory cytokines or other co-stimulatory 
molecules may promote CD4+ T cells to provide enhanced CD8+ T cell help to enhance 
tumor clearance.  This would suggest that Sorafenib may have an effect on MHC class II 
expression, but that remains unknown. While the mechanism of Sorafenib does not rely 
solely on macrophages (Chapter 2), this data suggests that Sorafenib may be re-educating 
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Chapter 5: Sorafenib Can Be Effective Combined with Cellular Immunotherapy 
Introduction: 
Advances in the treatment for metastatic breast cancer have improved the quality of life 
and conferred a small survival benefit for some patients.  However, disease relapse often 
occurs due to development of drug resistance and, ultimately, metastatic disease remains 
incurable1.  Therefore, there is a need for new therapeutic strategies to evade the 
development of drug resistance in these patients.  Consequently, ongoing efforts have 
focused on recruiting patients’ own immune cells as a therapeutic partner to combat 
disease. 
Cancer vaccines aim to reprogram host immune cells to become more efficient at targeting 
and killing cancer cells, leaving normal cell unharmed.  A whole cell granulocyte 
macrophage colony-stimulating factor (GM-CSF)-secreting vaccine targeting HER-2 was 
designed to enhance the immune response to breast cancer2. However, central and 
peripheral tolerance mechanisms limit the efficacy of vaccination.  Multiple studies have 
shown an increase in vaccine activity by strategically combining vaccine with other cancer 
therapeutics to take advantage of both the cytoreductive potential of cancer drugs and the 
ability to interrupt immunoregulatory networks and support productive anti-tumor immune 
responses3-5.    
Accordingly, a vaccination strategy incorporating multi-kinase inhibitors that target both 
the tumor cells, and other distinct cellular components within the tumor microenvironment 
is being developed.  A novel immune-modulating activity for the Sorafenib has been 
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previously reported (Chapter 2).   Sorafenib alone alone cures tumor-bearing FVB/N mice 
through both anti-angiogenic and immune effects.  
These studies have been extended to explore the activity the small molecule multi-kinase 
inhibitor, Sorafenib.  This study aims to determine the efficacy of combining Sorafenib 
with whole cell GMSCF-secreting breast cancer vaccine in a pre-clinical model.  Anti-
tumor immunity and tumor regression were characterized following Sorafenib treatment in 
combination with vaccine.  Additionally, immune cell infiltrate was analyzed in single 
agent and combination therapy tumors.  Sorafenib in combination with vaccine enhanced 
tumor clearance and promoted increased overall survival relative to single agent therapy.  
Additionally, Sorafenib treatment did not inhibit productive vaccine-induced immune 
responses.  Finally, Sorafenib treatment enhanced vaccine-induced tumor clearance by 




Materials and Methods: 
Mice 
FVB/N mice were purchased from Harlan (Frederick, MD).  Clone 100 T-cell receptor 
(TCR) transgenic mice, derived from FVB/N mice, express the high-avidity, RNEU420-429–
specific TCR in the majority of peripheral CD8+ T cells, and were generated as previously 
described6.  Eight to twelve week old mice were used in the experiments.  Animals were 
housed in pathogen-free conditions and were treated in accordance with institutional and 
AAALAC policies. All protocols were approved by the Animal Care and Use Committee 
of Johns Hopkins University. 
Reagents 
Sorafenib was purchased from LC Laboratories (Woburn, MA). FoxP3 PE-Cy5, CD25 PE, 
CD4 FITC, CD8 PE, GR1 PE, CD11b FITC, and Thy1.2 APC antibodies were obtained 
from eBioscience.   
Cell Lines and Media 
 The HER-2-expressing NT2.5 breast tumor cell line (derived from a spontaneous tumor 
explanted from a neu-N transgenic mouse), the GM-CSF–secreting vaccine cell lines, 
3T3GM (mock) and 3T3neuGM (HER-2-specific), and the T2Dq line were grown as 
previously described2. The cell lines used as T-cell targets, 3T3neuB7.1 and NT2.5B7.1, 






Tumors were fixed in formalin for 24 hours and paraffin embedded and sectioned at 5uM 
at the JHMI Pathology Core.  Sections were stained with H&E or retained for 
immunohistochemistry at the JHMI Oncology Tissue Service Center.  Cellular infiltrate 
staining was performed using antibodies for CD3, FoxP3, Gr1, and F480 (Cell Signaling).  
Immunohistochemistry was done with the Power Vision+ poly-HRP IHC Kit 
(ImmunoVision Inc). Antigen retrieval was carried out for 45 minutes in HTTR steam 
(Target Retrieval Solution; Dako) followed by incubation of primary antibody for 45 
minutes at room temperature.  Slides were incubated with Power Vision Poly-HRP anti-
rabbit IgG secondary antibody for 30 minutes at room temperature. Slides were developed 
with 3, 3’diaminobenzidine (Sigma Fast DAB tablets) and slides were counterstained with 
Dako Mayer’s hematoxylin (Sigma).  Images were captured under light microscopy at 20X 
magnification (E600, Nikon).  Three independent viewing fields were captured and 
staining was quantified using AR-Elements Microscope Imaging Software (Nikon).   
Drug treatment, vaccinations, and chemotherapy 
FVB/N mice were challenged subcutaneously with 5×106 NT2.5 tumor cells in the right 
mammary fat pad, followed by treatment 10-14 days later. Sorafenib (30 mg/kg) was 
administered daily Monday through Friday by oral gavage with a feeding needle. A viscous 
vehicle composed of 30% (w/v) Cremophor EL, 30% (w/v) PEG 400, and 10% ethanol, 
10% glucose (Sigma-Aldrich) was used as the Sorafenib diluent, and also administered as 
the vehicle treatment control.  3×106 vaccine cells per mouse were irradiated before 
subcutaneous injection in both hind limbs and the left front limb.  Doses and timing for 
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tumor cells and vaccinations have been previously optimized2.  For combination treatment 
studies, Sorafenib treatment began on the day of vaccination.  Mice were monitored for 
tumor growth and onset twice weekly. Tumor growth was determined by measuring tumor 
diameter in two perpendicular dimensions with calipers. Mean tumor size for an 
experimental group included only those mice with measureable tumors. 
ELISPOTS 
ELISPOTS were performed 14-17 days post-vaccination. Splenic CD8+ T cells were 
isolated from individual mice (not pooled) using the Dynabeads Untouched Mouse CD8 
Cell Negative Isolation Kit (Life Technologies). RNEU420-429 (PDSLRDLSVF) and NP118–
126 (RPQASGVYM) peptides were synthesized at 95% purity by the Oncology Peptide 
Synthesis Facility (Johns Hopkins, Baltimore, MD). 105 CD8+ T cells were incubated in 
triplicate with 104 peptide loaded T2Dq, NT2.5B7.1, or 3T3neuB7.1 target cells. 
NT2.5B7.1 and 3T3neuB7.1 cells were stimulated with IFN for 2 days prior to co-culture.  
T cell/T2Dq cells were co-cultured for 16 hours and T cell/NT2.5B7.1 or T 
cell/3T3neuB7.1 cells were co-cultured for 24 hours on pre-coated IFN-γ ELISPOT 
Multiscreen-HA plates (Millipore) according to the manufacturer’s protocols 
(Ebioscience).   ELISPOT plates were developed using an AEC staining kit (Sigma) 
according to the manufacturers’ instructions. IFN-secreting CD8+ T cells were 
enumerated using the Immunospot counter (Cellular Technology, Ltd.).  The average 
number of spots in control wells was subtracted from the average number of spots in each 





Adoptive Transfer Experiment 
Adoptive transfer was carried out as described previously8.  Briefly, FVB/N mice received 
subcutaneous injections of 5×106 NT2.5 cells into the right upper mammary fat pad.  One 
week post tumor challenge, mice were vaccinated with 3×106 irradiated 3T3neuGM cells 
or 3T3GM cells.  Sorafenib (30 mg/kg) or vehicle was given by daily gavage starting on 
the day of vaccination. CD8+ T cells were isolated from Clone 100 TCR transgenic mice 
by CD8 negative selection using Dynabeads Untouched Mouse CD8 negative isolation kit 
(Life Technologies).  4×106 CD8+ T cells per mouse were adoptively transferred via tail 
vein injection one day following initiation of treatment.  Spleens, lymph nodes, and tumors 
from adoptively transferred mice were harvested five days after adoptive transfer. Spleens 
and lymph nodes were collected and mashed through a 70uM cell strainer.  Tumors were 
minced and digested with Liberase TM (Roche) for 30 minutes and mashed through 70uM 
cell strainers.  Isolated single cell suspensions were analyzed for Thy1.2+ CD8+ cells on a 
Galios Flow Cytometer (BD Coulter) and data was analyzed with FlowJo software 
(Treestar, Inc.) 
Statistical Analysis 
Statistical analysis was conducted using GraphPad Prism Software using an unpaired, two-
tailed Student’s t-test, assuming equal population variances to determine the statistical 




Sorafenib can be effectively combined with GM-CSF-secreting cellular 
immunotherapy in FVB/N mice 
The therapeutic activity of Sorafenib was analyzed in the context of a GM-CSF-secreting, 
HER-2-overexpressing vaccine.  NT2.5 tumor regression was accelerated in FVB/N mice 
that received the HER-2-specific vaccine in combination with Sorafenib relative to mice 
treated with either single agent Sorafenib, mock vaccine, or vehicle control alone (Figure 
12A).  Mice receiving combination therapy also showed improved tumor-free survival 
compared with mice receiving either single agent therapy (Figure 12B).   
Sorafenib does not hinder vaccine-induced immune response 
Next, the effect of Sorafenib on vaccine-induced immune responses was analyzed. Splenic 
CD8+ T cell IFNproduction in response to tumor and vaccine cell targets was used to 
assay vaccine-induced immunity.  IFNγ production by splenic CD8+ T cells co-cultured 
with NT2.5 tumor cells or 3T3neu vaccine cells expressing B7.1 as targets was measured 
by ELISPOT. Sorafenib treatment alone did not induce a CD8+ T cell response to either 
NT2.5 tumor cells or vaccine cells; in contrast GM-CSF-secreting vaccination resulted in 
a robust CD8+ T cell response. Adding Sorafenib to vaccination did not inhibit the vaccine-
induced CD8+ T cell response to HER-2-expressing target cells (3T3neuB7.1 or 
NT2.5B7.1, Figure 12C). Additionally, vaccinated mice receiving Sorafenib developed 
RNEU420-429-specific CD8+ T cell responses as well as mice that received vaccine alone 
(Figure 12D).  These data show that Sorafenib does not interfere with vaccine-induced 
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immune responses and can be successfully combined with vaccination to enhance NT2.5 
tumor clearance in immune competent FVB/N mice. 
Sorafenib does not impede tumor infiltrating immune cells  
The effect of Sorafenib treatment on the ability of immune cells to infiltrate the tumor was 
also analyzed.  Tumors from vaccinated mice showed increased amounts of CD3+ T cells 
and CD68+ macrophages.  Sorafenib treatment did not alter the infiltration of these cells 
into the tumor as similar numbers of each cell type were present in both treatment settings 
(Figure 13A and C).  Treatment with vaccine alone or in combination with Sorafenib did 
not alter infiltrating Treg numbers relative to treatment control tumors. Staining for 
Ly6C/Ly6G, indicating the presence of granulocytic myeloid cells, was increased in mice 
that received vaccination in combination with Sorafenib.  
Sorafenib increases HER-2-specific T cell accumulation in the tumor 
To further evaluate the possible effect of Sorafenib therapy on the magnitude of the 
vaccine-induced locoregional T cell responses, adoptive T cell transfers with Clone 100 
TCR transgenic T cells specific for RNEU420-429 were performed. Vaccination alone was 
sufficient to increase the number of adoptively transferred antigen-specific Thy1.2+ CD8+ 
T cells in the spleen and vaccine-draining lymph nodes relative to either mock vaccination 
or Sorafenib added to mock vaccination.  HER-2 targeted vaccination also increased the 
number of T cells in the tumor relative to mock vaccination controls (Figure 14A-C). 
Combining Sorafenib with vaccine did not diminish the numbers of Thy1.2+ CD8+ cells 
found in the spleen and vaccine-draining lymph nodes (Figure 14A and B). Integrating 
Sorafenib with vaccination modestly increased the number of HER-2-specific T cells found 
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in the tumor (Figure 13C). These data suggest that Sorafenib may augment the ability of 
antigen-specific T cells generated by vaccination to accumulate in the tumor, thereby 
resulting in enhanced tumor clearance and tumor-free survival. Taken together, these data 
show that Sorafenib treatment may be effectively combined with HER-2 targeted DC-







Figure 12: Sorafenib can be effectively combined with vaccine in FVB/N mice. A, 
FVB/N mice (n=10) were tumor challenged on Day 0 and vaccinated and began daily 
Sorafenib or vehicle treatment on day 7 and followed for tumor growth and B, overall 
survival. C, FVB/N mice (n=10) were tumor challenged and at day 7 were vaccinated and 
began daily Sorafenib or vehicle treatment and 2 weeks post-vaccination, splenic CD8+ 
effector T cells were isolated and used for IFN ELISPOT with NT2.5B7.1 or 3T3neuB7.1 
as targets or D, with p50 or NP peptide pulsed T2dq cells as targets.  **, P < 0.01 and ***, 
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Figure 13: Sorafenib does not impede immune cell infiltration into the tumor. FVB/N 
mice (n=5) were tumor challenged on Day 0 and vaccinated and began daily Sorafenib or 
vehicle treatment on day 7.  Tumors were prepared for histological examination 3 weeks 
after drug treatment.  Immunohistochemistry to detect A, CD3, B, FoxP3, C, CD68, and 
D, Ly6C/Ly6G was performed at 20X magnification.   Staining was quantified using 
Elements software.  Graphs (mean + SD) are cell counts from 3-5 samples per group, *, P 
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Figure 14: Sorafenib increases HER-2-specific T cells in the tumor.  FVB/N mice (n=3) 
were tumor challenged and vaccinated and began daily Sorafenib treatment on day 7.  
Splenic CD8+ T cells were isolated from Clone100 mice and were adoptively transferred 
one day post-treatment. A, spleen, B, vaccine-draining lymph nodes and C, tumor were 
harvested 5 days post adoptive transfer and stained for antibodies specific for Thy1.2 and 
CD8.  Samples were analyzed by flow cytometry, with the number of positive cells 




































































































































































































































The data presented here show two important new findings.  First, the multi-kinase inhibitor 
of angiogenesis, Sorafenib, can be effectively combined with a DC-based vaccine in breast 
cancer. Second, combining vaccine with Sorafenib does not inhibit and may enhance 
vaccine-induced immunity.  Although past studies have discouraged the use of Sorafenib 
in combination with immunotherapy, these studies add to the recently accumulating 
literature supporting partnering Sorafenib with immunotherapy.  Given that single agent 
Sorafenib is often ineffective at producing lasting responses in breast cancer patients, these 
finding support repurposing Sorafenib in combination with immunotherapy as a new 
treatment avenue for breast cancer patients9. 
The observed immune dependent mechanism for Sorafenib supports its use in combination 
with immune activating therapy such as vaccination.  Therefore, the effect of combining 
Sorafenib with DC-based whole cell GM-CSF-secreting vaccine was examined.  Many 
reports have discouraged the use of Sorafenib as a partner with immunotherapy as it has 
been found to inhibit DC function, reducing maturation and migration, and inhibit the 
production of OVA-specific CD8+ T cell responses in vivo in mice pre-treated with 
Sorafenib followed by peptide vaccination with adjuvant10.   In vitro studies of 
lymphocytes from hepatocellular carcinoma patients demonstrated that pharmacologic 
doses of Sorafenib decreased effector T cell activation, whereas subpharmacologic doses 
selectively promoted the activation of effector T cells while blocking Treg function11.    
However, a growing body of evidence has since been published supporting the use of 
Sorafenib with combination immunotherapy.   Sorafenib was shown to have a therapeutic 
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benefit in murine colon cancer when combined with MC38-CEA TRICOM vaccine12.   In 
an E.G7/OT-1 murine model of adoptive cell therapy with low dose Sorafenib, Sorafenib 
decreased the expression of immunosuppressive factors, and enhanced functions and 
migrations of transferred CD8+ T cells through inhibition of STAT3 and other 
immunosuppressive factors13.    
The data reported here support the latter publications, demonstrating that incorporating 
Sorafenib with vaccine resulted in enhanced tumor clearance compared to single agent 
therapy.  Additionally, vaccine-induced immune response was effectively maintained with 
the addition of Sorafenib.  Sorafenib did not prevent vaccine-induced recruitment of CD3+ 
T cells to the tumor, suggesting that Sorafenib does not negatively affect the ability of T 
cells to gain access to the tumor to exert effector function.  Finally, combining Sorafenib 
with vaccine increased the accumulation of adoptively transferred tumor-specific CD8+ T 
cells in the tumor with combination therapy than with either single agent.  These data also 
support previous studies showing that angiogenesis inhibitors improve cellular 
immunotherapy14-16.   
Sorafenib treatment combined with vaccine also increased Ly6G/Ly6C+ cell infiltrate.  
Enhanced tumor clearance as a combination therapy would suggest that these cells are not 
myeloid-derived suppressor cells, although this needs to be further examined.   The 
increased in Ly6G/Ly6C staining may also suggest an increased neutrophilic infiltration in 
these tumors.  Prior reports have shown enhanced T cell dependent, tumor-specific 
protective immunity as a result of increased Fas mediated-neutrophilic interactions with 
FasL expressing cells within the tumor17,18.   It is possible that Sorafenib may alter the 
expression of FasL, a known chemoattractant of Fas-expressing neutrophils, within the 
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tumor microenvironment. Therefore, Sorafenib could be promoting a local neutrophil-
induced inflammatory response in the tumor based on the Fas/FasL interaction that when 
combined with increased antigen-specific T cells induced by vaccine, results in enhanced 
rate of tumor clearance.  However, this still has to be investigated.    
In conclusion, it is shown here for the first time, that Sorafenib can be effectively combined 
with DC-based, HER2-targeted cellular immunotherapy to enhance breast tumor clearance 
and improve tumor-free survival.  Due to its ability to target multiple aspects of the tumor 
microenvironment, including host tumor cells, endothelial cells, and immune cells, further 
studies utilizing Sorafenib in combination with other immunomodulatory treatments, such 
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